


**CUMULATIVE  
SUPPLEMENT 3  
MARCH 2020**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2020**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40<sup>th</sup> EDITION**

**Cumulative Supplement 3  
March 2020**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Product Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 3  
MARCH 2020**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

AMNEAL PHARMACEUTICALS CO GMBH  
(AMNEAL PHARMS CO)

AMNEAL EU LTD  
(AMNEAL EU)

ANDA REPOSITORY LLC  
(ANDA REPOSITORY)

PHARMACEUTICS INTERNATIONAL INC  
(PII)

AMERICAN ANTIBIOTICS INC  
(AM ANTIBIOTICS)

BELCHER PHARMACEUTICALS INC  
(BELCHER PHARMS)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2019</u>	<u>MAR</u> <u>2020</u>	<u>JUN</u> <u>2020</u>	<u>SEP</u> <u>2020</u>	<u>DEC</u> <u>2020</u>
DRUG PRODUCTS	20567	20367			
LISTED SINGLE	2743	2635			
SOURCE	(13.3%)	(12.9%)			

MULTISOURCE	17824 (86.7%)	17732 (87.1%)
THERAPEUTICALLY EQUIVALENT	17740 (86.3%)	17659 (86.7%)
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)	73 (0.4%)
EXCEPTIONS <sup>4</sup>	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	17	24
NUMBER OF APPLICANTS	1162	1166

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration

CFTG Change. A TE Code is added when a first time generic for an innovator is approved.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug

CHRS Change. Reference Standard

CTEC Change. Therapeutic Equivalence Code

CTNA Change. Trade Name

DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.



OINTMENT; TOPICALACYCLOVIR

>A>	AB	SOLARIS PHARMA CORP	5%	A212495	001	Apr 07, 2020	Mar NEWA
	AB	XIROMED	5%	A201501	001	Jan 29, 2020	Jan NEWA

TABLET; ORALACYCLOVIR

	AB	! HETERO LABS LTD V	800MG	A203834	002	Oct 29, 2013	Jan CHRS
		ZOVIRAX					
		+ @ MYLAN	400MG	N020089	001	Apr 30, 1991	Jan DISC
		+ @	800MG	N020089	002	Apr 30, 1991	Jan DISC

ADAPALENEGEL; TOPICALADAPALENE

>D>	AB	GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010	Mar CMS1
-----	----	-------------------	------	---------	-----	--------------	----------

ALBUTEROL SULFATEAEROSOL, METERED; INHALATIONALBUTEROL SULFATE

>A>							
>A>	AB1	CIPLA	EQ 0.09MG BASE/INH	A209959	001	Apr 08, 2020	Mar NFTG
>D>	AB	PERRIGO PHARMS CO	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CTEC
>A>	AB2		EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CTEC
	AB		EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Feb NFTG
		PROAIR HFA					
>D>	AB	! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Mar CTEC
>A>	AB2	! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Mar CTEC
	AB	! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Feb CFTG
		PROVENTIL-HFA					
>D>	BX	! 3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	Mar CFTG
>A>	AB1	! 3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	Mar CFTG

SOLUTION; INHALATIONALBUTEROL SULFATE

		@ BAUSCH AND LOMB	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Feb DISC
	AN	! NEPHRON	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb CHRS

TABLET, EXTENDED RELEASE; ORALVOLMAX

>D>		@ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992	Mar CRLD
>A>		+ @	EQ 4MG BASE	N019604	002	Dec 23, 1992	Mar CRLD
>D>		@	EQ 8MG BASE	N019604	001	Dec 23, 1992	Mar CRLD
>A>		+ @	EQ 8MG BASE	N019604	001	Dec 23, 1992	Mar CRLD

ALPRAZOLAMTABLET; ORALALPRAZOLAM

		@ DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb DISC
		@	0.5MG	A074174	002	Oct 19, 1993	Feb DISC
		@	1MG	A074174	003	Oct 19, 1993	Feb DISC
		@	2MG	A074174	004	Oct 19, 1993	Feb DISC

AMANTADINE HYDROCHLORIDECAPSULE; ORALAMANTADINE HYDROCHLORIDE

	AB	INVATECH	100MG	A210129	001	Mar 02, 2020	Feb NEWA
--	----	----------	-------	---------	-----	--------------	----------

TABLET; ORALAMANTADINE HYDROCHLORIDE

	AB	INVATECH	100MG	A210215	001	Mar 10, 2020	Feb NEWA
--	----	----------	-------	---------	-----	--------------	----------

AMIKACIN SULFATEINJECTABLE; INJECTIONAMIKACIN SULFATE

>D>		@ TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar CMFD
>A>	AP	@ TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar CMFD

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OILEMULSION; INTRAVENOUSPERIKABIVEN IN PLASTIC CONTAINER

		! FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan CHRS
--	--	----------------------	---	---------	-----	--------------	----------

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

AA	VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb	NEWA
----	------------	------------	---------	-----	--------------	-----	------

AMISULPRIDE

SOLUTION;INTRAVENOUS

BARHEMSYS

+!	ACACIA PHARMA LTD	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Feb	NEWA
----	-------------------	--------------------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SANDOZ	10MG	A085968	004		Jan	CMS1	
AB	!	25MG	A085968	002		Jan	CMS1	
AB		75MG	A085968	006		Jan	CMS1	
AB		100MG	A085968	003		Jan	CMS1	
AB		150MG	A085968	005		Jan	CMS1	
>A>	AB	UPSHER SMITH LABS	25MG	A212654	001	Apr 07, 2020	Mar	NEWA

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

@ HIKMA

EQ 2.5MG BASE

A077262	001	Jul 09, 2007	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 5MG BASE

A077262	002	Jul 09, 2007	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 10MG BASE

A077262	003	Jul 09, 2007	Feb	DISC
---------	-----	--------------	-----	------

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CMFD
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CMFD
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CMFD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	AUROBINDO PHARMA LTD	5MG;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar	CPOT
>A>	AB		EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar	CPOT
>D>	AB		5MG;25MG;160MG	A206180	002	Dec 19, 2017	Mar	CPOT
>A>	AB		EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017	Mar	CPOT
>D>	AB		10MG;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar	CPOT
>D>	AB		10MG;25MG;160MG	A206180	004	Dec 19, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017	Mar	CPOT
>D>	AB		10MG;25MG;320MG	A206180	005	Dec 19, 2017	Mar	CPOT
>A>	AB		EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017	Mar	CPOT
>D>	AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar	CPOT
>A>	AB		EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar	CPOT
>D>	AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	Mar	CPOT
>A>	AB		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Mar	CPOT
>D>	AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar	CPOT
>A>	AB		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar	CPOT
>D>	AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	Mar	CPOT
>A>	AB		EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Mar	CPOT
>D>	AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	Mar	CPOT
>A>	AB		EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Mar	CPOT
>D>	AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar	CPOT
>A>	AB		EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar	CPOT
>D>	AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	Mar	CPOT
>A>	AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Mar	CPOT
>D>	AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar	CPOT
>A>	AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar	CPOT
>D>	AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	Mar	CPOT

## TABLET;ORAL

## AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Mar	CPOT			
>D>	AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	Mar	CPOT			
>A>	AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Mar	CPOT			
>D>		@ TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar	CPOT			
>A>		@	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar	CPOT			
>D>		@	5MG;25MG;160MG	A200435	002	Sep 25, 2012	Mar	CPOT			
>A>		@	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012	Mar	CPOT			
>D>		@	10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar	CPOT			
>A>		@	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar	CPOT			
>D>		@	10MG;25MG;160MG	A200435	003	Sep 25, 2012	Mar	CPOT			
>A>		@	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012	Mar	CPOT			
>D>		@	10MG;25MG;320MG	A200435	004	Sep 25, 2012	Mar	CPOT			
>A>		@	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012	Mar	CPOT			
>D>		@ TORRENT	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar	CPOT			
>A>		@	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar	CPOT			
>D>		@	5MG;25MG;160MG	A201593	002	Jun 03, 2015	Mar	CPOT			
>A>		@	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015	Mar	CPOT			
>D>		@	10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar	CPOT			
>A>		@	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar	CPOT			
>D>		@	10MG;25MG;160MG	A201593	004	Jun 03, 2015	Mar	CPOT			
>A>		@	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015	Mar	CPOT			
>D>		@	10MG;25MG;320MG	A201593	005	Jun 03, 2015	Mar	CPOT			
>A>		@	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015	Mar	CPOT			
EXFORGE HCT											
>D>	AB	+	NOVARTIS			5MG;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar	CPOT
>A>	AB	+				EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar	CPOT
>D>	AB	+				5MG;25MG;160MG	N022314	002	Apr 30, 2009	Mar	CPOT
>A>	AB	+				EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009	Mar	CPOT
>D>	AB	+				10MG;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar	CPOT
>A>	AB	+				EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar	CPOT
>D>	AB	+				10MG;25MG;160MG	N022314	004	Apr 30, 2009	Mar	CPOT
>A>	AB	+				EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009	Mar	CPOT
>D>	AB	+				10MG;25MG;320MG	N022314	005	Apr 30, 2009	Mar	CPOT
>A>	AB	+				EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009	Mar	CPOT

AMOXAPINE

## TABLET;ORAL

## AMOXAPINE

@	WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989	Jan	CMS1
@		50MG	A072419	001	Aug 01, 1989	Jan	CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## CAPSULE, EXTENDED RELEASE;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	CAHN
AB		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	CAHN
AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	CAHN
	@ NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jan	DISC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jan	DISC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jan	DISC
	@	5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jan	DISC
	@	6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jan	DISC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jan	DISC

## TABLET;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	BIONPHARMA INC	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Mar	NEWA
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Mar	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Mar	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Mar	NEWA
>A>	AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Mar	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Mar	NEWA

AMPHETAMINE SULFATE

## TABLET;ORAL

## AMPHETAMINE SULFATE

AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan	NEWA
AA		10MG	A212582	002	Feb 04, 2020	Jan	NEWA
AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb	NEWA

		TABLET;ORAL								
		AMPHETAMINE SULFATE								
AA			10MG		A211861	002	Mar 11, 2020	Feb	NEWA	
		<u>AMPHOTERICIN B</u>								
		INJECTABLE;INJECTION								
		AMPHOTERICIN B								
	!	XGEN PHARMS	50MG/VIAL		A063206	001	Apr 29, 1992	Feb	CAHN	
		<u>AMPICILLIN SODIUM; SULBACTAM SODIUM</u>								
		INJECTABLE;INJECTION								
		AMPICILLIN AND SULBACTAM								
	@	PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL		A065316	001	Jun 29, 2007	Jan	CAHN	
	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL		A065316	002	Jun 29, 2007	Jan	CAHN	
		<u>AMPICILLIN/AMPICILLIN TRIHYDRATE</u>								
		CAPSULE;ORAL								
		AMPICILLIN TRIHYDRATE								
>D>	AB	!	DAVA PHARMS INC	EQ 500MG BASE	A062882	001	Feb 25, 1988	Mar	DISC	
>A>		@		EQ 500MG BASE	A062882	001	Feb 25, 1988	Mar	DISC	
>D>	AB		SANDOZ	EQ 500MG BASE	A064082	002	Aug 29, 1995	Mar	CHRS	
>A>		!		EQ 500MG BASE	A064082	002	Aug 29, 1995	Mar	CHRS	
		<u>ANASTROZOLE</u>								
		TABLET;ORAL								
		ANASTROZOLE								
	@	APOTEX INC	1MG		A200654	001	May 11, 2012	Feb	DISC	
	@	MYLAN	1MG		A091051	001	Jun 28, 2010	Jan	DISC	
		<u>APIXABAN</u>								
		TABLET;ORAL								
		APIXABAN								
>A>	AB		BIONPHARMA INC	2.5MG	A210152	001	Apr 08, 2020	Mar	NEWA	
>A>	AB			5MG	A210152	002	Apr 08, 2020	Mar	NEWA	
	@	MYLAN	2.5MG		A210128	001	Dec 23, 2019	Jan	DISC	
	@		5MG		A210128	002	Dec 23, 2019	Jan	DISC	
		<u>ARGATROBAN</u>								
		INJECTABLE;INJECTION								
		ARGATROBAN								
>D>	AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CRLD	
>A>	AP	+	!	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CHRS	
>A>	AP	+		250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CRLD	
		INJECTABLE;INTRAVENOUS								
>D>			ARGATROBAN IN 0.9% SODIUM CHLORIDE							
>D>			TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Mar	DISC	
>A>		@		250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Mar	DISC	
		<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE</u>								
		INJECTABLE;INJECTION								
		SEPTOCAINE								
>D>	AP	+	!	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Mar	CTEC
>A>		+	!		4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Mar	CTEC
		+	!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb	CTEC
>D>			ULTACAN							
>D>	AP		HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Mar	DISC	
>A>		@		4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Mar	DISC	
			ULTACAN FORTE							
	@		HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Feb	DISC	
		<u>ASENAPINE MALEATE</u>								
		TABLET;SUBLINGUAL								
		SAPHRIS								
	+		ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan	CMS1	



ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AA	PII	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Mar	CAHN
>A>	AA	STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Mar	CAHN

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

@ MYLAN

EQ 150MG BASE

A208177 001 Sep 24, 2018 Feb DISC

@

EQ 200MG BASE

A208177 002 Sep 24, 2018 Feb DISC

@

EQ 300MG BASE

A208177 003 Sep 24, 2018 Feb DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB LUPIN LTD

EQ 10MG BASE

A204991 001 Mar 06, 2019 Jan CMFD

AB

EQ 20MG BASE

A204991 002 Mar 06, 2019 Jan CMFD

AB

EQ 40MG BASE

A204991 003 Mar 06, 2019 Jan CMFD

AB

EQ 80MG BASE

A204991 004 Mar 06, 2019 Jan CMFD

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

&gt;A&gt; SCOV3

EQ 10MG BASE;10MG

A206084 001 Apr 26, 2017 Mar CAHN

&gt;A&gt;

EQ 20MG BASE;10MG

A206084 002 Apr 26, 2017 Mar CAHN

&gt;A&gt;

EQ 40MG BASE;10MG

A206084 003 Apr 26, 2017 Mar CAHN

&gt;A&gt;

!

EQ 80MG BASE;10MG

A206084 004 Apr 26, 2017 Mar CAHN

&gt;D&gt;

WATSON LABS TEVA

EQ 10MG BASE;10MG

A206084 001 Apr 26, 2017 Mar CAHN

&gt;D&gt;

EQ 20MG BASE;10MG

A206084 002 Apr 26, 2017 Mar CAHN

&gt;D&gt;

EQ 40MG BASE;10MG

A206084 003 Apr 26, 2017 Mar CAHN

&gt;D&gt;

!

EQ 80MG BASE;10MG

A206084 004 Apr 26, 2017 Mar CAHN

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ISOPTO ATROPINE

+! ALCON LABS INC

1%

N208151 001 Dec 01, 2016 Feb CRDL

!

1%

N208151 001 Dec 01, 2016 Feb CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA LEADING PHARMA LLC 0.025MG;2.5MG

A213413 001 Feb 20, 2020 Feb NEWA

AVAPRITINIB

TABLET; ORAL

AYVAKIT

+ BLUEPRINT MEDICINES

100MG

N212608 001 Jan 09, 2020 Jan NEWA

+

200MG

N212608 002 Jan 09, 2020 Jan NEWA

+!

300MG

N212608 003 Jan 09, 2020 Jan NEWA

AZATHIOPRINE

TABLET; ORAL

AZATHIOPRINE

&gt;A&gt; AB ALKEM LABS LTD

25MG

A208687 001 Mar 27, 2020 Mar NEWA

&gt;A&gt; AB

50MG

A208687 002 Mar 27, 2020 Mar NEWA

&gt;A&gt; AB

75MG

A208687 003 Mar 27, 2020 Mar NEWA

&gt;A&gt; AB

100MG

A208687 004 Mar 27, 2020 Mar NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT GLAND PHARMA LTD 0.05%

A210092 001 Feb 25, 2020 Feb NEWA

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

&gt;D&gt; @ CSPC OUYI

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007 Mar CAHN

&gt;A&gt;

@ HIKMA

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007 Mar CAHN

&gt;D&gt; AP

MYLAN LABS LTD

EQ 500MG BASE/VIAL

A204732 001 Jan 26, 2017 Mar DISC

&gt;A&gt;

@

EQ 500MG BASE/VIAL

A204732 001 Jan 26, 2017 Mar DISC

## TABLET; ORAL

## AZITHROMYCIN

AB	ALEMBIC PHARMS LTD	EQ 250MG BASE	A211791	001	Jan 28, 2020	Jan NEWA
AB		EQ 500MG BASE	A211792	001	Jan 28, 2020	Jan NEWA
AB		EQ 600MG BASE	A211793	001	Jan 27, 2020	Jan NEWA
	@ MYLAN	EQ 600MG BASE	A065360	001	Jan 08, 2007	Jan DISC

BACITRACIN

## INJECTABLE; INJECTION

>D>	BACIIM						
>D>	AP	X GEN PHARMS	50,000 UNITS/VIAL	A064153	001	May 09, 1997	Mar DISC
>A>		@	50,000 UNITS/VIAL	A064153	001	May 09, 1997	Mar DISC
		BACITRACIN					
>D>	AP	AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Mar DISC
>A>		@	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Mar DISC
>D>	AP	FRESENIUS KABI USA	50,000 UNITS/VIAL	A065116	001	Dec 03, 2002	Mar DISC
>A>		@	50,000 UNITS/VIAL	A065116	001	Dec 03, 2002	Mar DISC

BACLOFEN

## INJECTABLE; INTRATHECAL

		BACLOFEN					
>D>	AP	MAIA PHARMS INC	0.5MG/ML	A210048	001	Sep 11, 2019	Mar DISC
>A>		@	0.5MG/ML	A210048	001	Sep 11, 2019	Mar DISC
>D>	AP		2MG/ML	A210048	002	Sep 11, 2019	Mar DISC
>A>		@	2MG/ML	A210048	002	Sep 11, 2019	Mar DISC

## TABLET; ORAL

## BACLOFEN

	@ MYLAN	20MG	A077121	002	Jul 29, 2005	Jan DISC
--	---------	------	---------	-----	--------------	----------

BEMPEDOIC ACID

## TABLET; ORAL

## NEXLETOL

+!	ESPERION THERAPS INC	180MG	N211616	001	Feb 21, 2020	Feb NEWA
----	----------------------	-------	---------	-----	--------------	----------

BEMPEDOIC ACID; EZETIMIBE

## TABLET; ORAL

## NEXLIZET

+!	ESPERION THERAPS INC	180MG;10MG	N211617	001	Feb 26, 2020	Feb NEWA
----	----------------------	------------	---------	-----	--------------	----------

BENZAEPRIIL HYDROCHLORIDE

## TABLET; ORAL

## BENZAEPRIIL HYDROCHLORIDE

AB	COREPHARMA	5MG	A077128	001	Mar 08, 2006	Feb CAHN
AB		10MG	A077128	002	Mar 08, 2006	Feb CAHN
AB		20MG	A077128	003	Mar 08, 2006	Feb CAHN
AB		40MG	A077128	004	Mar 08, 2006	Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

## SOLUTION/DROPS; OPHTHALMIC

## FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

>A>	+!	BAUSCH	0.4%;0.3%	N211039	001	Mar 09, 2020	Mar NEWA
-----	----	--------	-----------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

## TABLET; ORAL

## BENZPHETAMINE HYDROCHLORIDE

>D>	AA	EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Mar DISC
>A>		@	50MG	A202061	001	Jan 27, 2012	Mar DISC

BEPOTASTINE BESILATE

## SOLUTION/DROPS; OPHTHALMIC

## BEPOTASTINE BESILATE

	@ MYLAN	1.5%	A206220	001	Mar 18, 2019	Feb DISC
--	---------	------	---------	-----	--------------	----------

## BEPREVE

+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb CTEC
----	---------------------	------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

## CREAM, AUGMENTED; TOPICAL

## BETAMETHASONE DIPROPIONATE

AB	!	GLENMARK GENERICS	EQ 0.05% BASE	A078930	001	Sep 23, 2008	Feb CHRS
		DIPROLENE AF					
	+ @	MERCK SHARP DOHME	EQ 0.05% BASE	N019555	001	Apr 27, 1987	Feb DISC

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	!	AMNEAL PHARM	5MG	A040855	001	Nov 21, 2007	Jan	CHRS
AA	!		10MG	A040855	002	Nov 21, 2007	Jan	CHRS
AA	!		25MG	A040855	003	Nov 21, 2007	Jan	CHRS
	@	IMPAX LABS	25MG	A040721	003	Nov 01, 2006	Jan	CMS1
		URECHOLINE						
	@	ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985	Jan	DISC
	@		10MG	A088440	001	May 29, 1984	Jan	DISC
	@		25MG	A088441	001	May 29, 1984	Jan	DISC

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB		ANI PHARMS INC	75MG	A209861	001	May 08, 2018	Jan	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

	@	MYLAN	50MG	A079185	001	Jul 06, 2009	Jan	DISC
--	---	-------	------	---------	-----	--------------	-----	------

BIMATOPROST

&gt;A&gt; IMPLANT; OPHTHALMIC

&gt;A&gt; DURYSTA

>A>	+	ALLERGAN INC	10MCG	N211911	001	Mar 04, 2020	Mar	NEWA
-----	---	--------------	-------	---------	-----	--------------	-----	------

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT		ALEMBIC PHARMS LTD	0.03%	A210515	001	Jan 21, 2020	Jan	NEWA
----	--	--------------------	-------	---------	-----	--------------	-----	------

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

	@	APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017	Feb	DISC
--	---	--------	------------	---------	-----	--------------	-----	------

BOSENTAN

TABLET; ORAL

BOSENTAN

AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan	NEWA
AB			125MG	A211461	002	Jan 23, 2020	Jan	NEWA
	@	MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan	DISC
	@		125MG	A205173	002	Jan 15, 2020	Jan	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

>A>	AT2	GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar	NEWA
-----	-----	------------------	---------------	---------	-----	--------------	-----	------

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Feb	CAHN
--	---	-------	---------------	---------	-----	--------------	-----	------

BUMETANIDE

TABLET; ORAL

BUMETANIDE

AB		RISING	0.5MG	A212019	001	Dec 12, 2019	Jan	CAHN
AB			1MG	A212019	002	Dec 12, 2019	Jan	CAHN
AB			2MG	A212019	003	Dec 12, 2019	Jan	CAHN

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

>A>	AB	AMNEAL PHARMS LLC	5MCG/HR	A211586	001	Apr 14, 2020	Mar	NEWA
>A>	AB		7.5MCG/HR	A211586	002	Apr 14, 2020	Mar	NFTG
>A>	AB		10MCG/HR	A211586	003	Apr 14, 2020	Mar	NEWA
>A>	AB		15MCG/HR	A211586	004	Apr 14, 2020	Mar	NEWA
>A>	AB		20MCG/HR	A211586	005	Apr 14, 2020	Mar	NEWA

BUTRANS

>D>	+	PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Mar	CFTG
>A>	AB	+	7.5MCG/HR	N021306	005	Jun 30, 2014	Mar	CFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	AB	RHODES PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Mar NEWA
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Mar NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB		CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan NEWA
AB			100MG	A208606	002	Jan 16, 2020	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

@	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb DISC
@		150MG	A202774	002	Oct 11, 2013	Feb DISC
@		150MG	A202775	001	Oct 11, 2013	Feb DISC
@		150MG	A207459	001	Jun 30, 2017	Feb DISC
@		200MG	A202774	003	Oct 11, 2013	Feb DISC
@		300MG	A207459	002	Jun 30, 2017	Feb DISC

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jan CAHN
---	---	------------	----------	---------	-----	--------------	----------

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

@	MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Feb DISC
---	----------------	--------	---------	-----	--------------	----------

CABERGOLINE

TABLET;ORAL

CABERGOLINE

@	MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jan DISC
---	-------	-------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

>D>		@	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Mar CMFD
>A>	AB			0.25MCG	A204556	001	Feb 21, 2019	Mar CMFD
>D>		@		0.5MCG	A204556	002	Feb 21, 2019	Mar CMFD
>A>	AB			0.5MCG	A204556	002	Feb 21, 2019	Mar CMFD

INJECTABLE;INJECTION

CALCITRIOL

AP	!	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan CTEC
AP		GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

@	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jan DISC
AB	SUVEN LIFE	667MG	A211038	001	Feb 21, 2020	Feb NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPREOMYCIN SULFATE

>D>	AP	HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796	001	Oct 18, 2018	Mar DISC
>A>		@	EQ 1GM BASE/VIAL	A204796	001	Oct 18, 2018	Mar DISC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Feb CAHN
@		25MG	A074737	002	Oct 28, 1998	Feb CAHN
@		50MG	A074737	003	Oct 28, 1998	Feb CAHN
@		100MG	A074737	004	Oct 28, 1998	Feb CAHN

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

>D>	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Mar	CTEC
>A>	AB	100MG	A077272	001	Dec 07, 2005	Mar	CTEC
>A>	UMEDICA LABS PVT LTD	100MG	A207798	001	Apr 15, 2020	Mar	NEWA
>A>	AB	200MG	A207798	002	Apr 15, 2020	Mar	NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

+ @	MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	DISC
-----	-------------------	------------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

>D>	AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	DISC
>A>		@	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	DISC
>D>	AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	DISC
>A>		@	150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	DISC
>D>	AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	DISC
>A>		@	450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	DISC

CARFILZOMIB

POWDER; INTRAVENOUS

CARFILZOMIB

>A>	AP	APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020	Mar	NFTG
>A>	AP		60MG/VIAL	A209425	001	Mar 16, 2020	Mar	NEWA
		KYPROLIS						
>D>		+ ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Mar	CFTG
>A>	AP	+	30MG/VIAL	N202714	002	Jun 03, 2016	Mar	CFTG

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

@	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

@	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan	DISC
---	--------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

SUPRAX

@	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004	Jan	DISC
---	--------------	-------	---------	-----	--------------	-----	------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN PLASTIC CONTAINER

>D>	!	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Mar	DISC
>A>		@	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Mar	DISC
>D>	!		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Mar	DISC
>A>		@	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Mar	DISC

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

@	HOSPIRA INC	EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan	DISC
---	-------------	-------------------	---------	-----	--------------	-----	------

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB	TIANJIN TIANYAO	50MG	A207872	001	Feb 25, 2020	Feb	NEWA
AB		100MG	A207872	002	Feb 25, 2020	Feb	NEWA
AB		200MG	A207872	003	Feb 25, 2020	Feb	NEWA
AB		400MG	A207872	004	Feb 25, 2020	Feb	NEWA
AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan	CDFR

CAPSULE;ORAL  
CELECOXIB

AB		100MG	A210628	002	Nov 27, 2019	Jan CDFR
AB		200MG	A210628	003	Nov 27, 2019	Jan CDFR
AB		400MG	A210628	004	Nov 27, 2019	Jan CDFR
AB	YILING PHARM LTD	50MG	A211412	001	Mar 06, 2020	Feb NEWA
AB		100MG	A211412	002	Mar 06, 2020	Feb NEWA
AB		200MG	A211412	003	Mar 06, 2020	Feb NEWA
AB		400MG	A211412	004	Mar 06, 2020	Feb NEWA

>A> CENOBAMATE

&gt;A&gt; TABLET;ORAL

&gt;A&gt; XCOPRI

>A>	+	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Mar NEWA
>A>	+		25MG	N212839	002	Mar 10, 2020	Mar NEWA
>A>	+		50MG	N212839	003	Mar 10, 2020	Mar NEWA
>A>	+		100MG	N212839	004	Mar 10, 2020	Mar NEWA
>A>	+		150MG	N212839	005	Mar 10, 2020	Mar NEWA
>A>	+	!	200MG	N212839	006	Mar 10, 2020	Mar NEWA

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

	@	HIKMA PHARMS	EQ 150MG BASE	A083082	001		Feb DISC
AA	!	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb CHRS

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan NEWA
AB		25MG	A213368	002	Jan 17, 2020	Jan NEWA
AB		50MG	A213368	003	Jan 17, 2020	Jan NEWA
AB		100MG	A213368	004	Jan 17, 2020	Jan NEWA
AB		200MG	A213368	005	Jan 17, 2020	Jan NEWA

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan NEWA
AB		50MG	A213412	002	Feb 11, 2020	Jan NEWA
AB	VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb CAHN
AB		50MG	A211063	002	Feb 26, 2019	Feb CAHN

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

>A>	AB	AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A211119	001	Apr 06, 2020	Mar NEWA
>A>	AB		EQ 4GM RESIN/SCOOPFUL	A211119	002	Apr 06, 2020	Mar NEWA
		LOCHOLEST					
		@ ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb CAHN
		@ INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan CAHN
		LOCHOLEST LIGHT					
		@ ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

>D>		@ TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar CMFD
>A>	AB		EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar CMFD
>D>		@	EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar CMFD
>A>	AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar CMFD

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

@ LUPIN LTD

@

@

	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan DISC
	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan DISC
	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan DISC

CISATRACURIUM BESYLATEINJECTABLE;INJECTION  
CISATRACURIUM BESYLATE

AP	HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan	CMFD
----	-------------	----------------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDETABLET;ORAL  
CITALOPRAM HYDROBROMIDE

>D>	AB	JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar	DISC
>A>		@	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar	DISC
>D>	AB		EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar	DISC
>A>		@	EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar	DISC
>D>	AB		EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar	DISC
>A>		@	EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar	DISC

CLINDAMYCIN PHOSPHATEAEROSOL, FOAM;TOPICAL  
CLINDAMYCIN PHOSPHATE

AT	TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	Feb	NEWA
----	---------------------	----	---------	-----	--------------	-----	------

CLOBAZAMSUSPENSION;ORAL  
CLOBAZAM

AB	HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb	NEWA
----	---------------------	----------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATECREAM;TOPICAL  
CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan	NEWA
-----	----------------------	-------	---------	-----	--------------	-----	------

SPRAY;TOPICAL  
CLOBETASOL PROPIONATE  
@ ALEOR DERMACEUTICALS 0.05%

A211191	001	Oct 02, 2019	Jan	DISC
---------	-----	--------------	-----	------

CLOMIPRAMINE HYDROCHLORIDECAPSULE;ORAL  
CLOMIPRAMINE HYDROCHLORIDE

AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan	NEWA	
AB		50MG	A211364	002	Feb 07, 2020	Jan	NEWA	
AB		75MG	A211364	003	Feb 07, 2020	Jan	NEWA	
AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan	CMFD	
AB		50MG	A211767	002	Apr 08, 2019	Jan	CMFD	
AB		75MG	A211767	003	Apr 08, 2019	Jan	CMFD	
	@ TEVA	25MG	A074958	001	Aug 26, 1997	Feb	DISC	
	@	50MG	A074958	002	Aug 26, 1997	Feb	DISC	
	@	75MG	A074958	003	Aug 26, 1997	Feb	DISC	
>A>	AB	TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Mar	NEWA
>A>	AB		50MG	A210653	002	Apr 03, 2020	Mar	NEWA
>A>	AB		75MG	A210653	003	Apr 03, 2020	Mar	NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE;INJECTION  
CLONIDINE HYDROCHLORIDE

AP	XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb	CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL  
CLONIDINE HYDROCHLORIDE

AB1	UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	Feb	CMFD
-----	-------------------	-------	---------	-----	--------------	-----	------

CLORAZEPATE DIPOTASSIUMCAPSULE;ORAL  
CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 26, 1988	Feb	CMS1
@	7.5MG	A072112	003	Aug 26, 1988	Feb	CMS1

COCAINE HYDROCHLORIDESOLUTION;NASAL  
NUMBRINO

CODY LABS INC	4%	N209575	001	Jan 10, 2020	Jan	NEWA
---------------	----	---------	-----	--------------	-----	------

COLCHICINETABLET; ORAL  
COLCHICINE

AB	AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan	CMFD
AB	GRANULES PHARMS	0.6MG	A210425	001	Feb 05, 2020	Jan	NEWA

COLISTIMETHATE SODIUMINJECTABLE; INJECTION  
COLISTIMETHATE SODIUM

AP	XGEN PHARMS	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Feb	CAHN
----	-------------	--------------------	---------	-----	--------------	-----	------

CYCLOPHOSPHAMIDECAPSULE; ORAL  
CYCLOPHOSPHAMIDE

AB	ANI PHARMS INC	25MG	A207014	001	Mar 19, 2018	Jan	CAHN
AB		50MG	A207014	002	Mar 19, 2018	Jan	CAHN

CYPROHEPTADINE HYDROCHLORIDETABLET; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	APPCO	4MG	A206553	001	Nov 29, 2016	Mar	CAHN
>D>	AA	TWI PHARMS	4MG	A206553	001	Nov 29, 2016	Mar	CAHN

CYSTEAMINE BITARTRATEGRANULE; ORAL  
PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Feb	NEWA
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Feb	NEWA

DABIGATRAN ETEXILATE MESYLATECAPSULE; ORAL  
DABIGATRAN ETEXILATE MESYLATE

AB	ALKEM LABS LTD	EQ 75MG BASE	A208040	001	Mar 11, 2020	Feb	NFTG	
AB		EQ 150MG BASE	A208040	002	Mar 11, 2020	Feb	NFTG	
		PRADAXA						
AB	+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb	CFTG
AB	+	!	EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb	CFTG

DACTINOMYCININJECTABLE; INJECTION  
DACTINOMYCIN

AP	XGEN PHARMS	0.5MG/VIAL	A203999	001	May 20, 2019	Feb	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

DAPSONEGEL; TOPICAL  
DAPSONE

AB	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Feb	NEWA
----	-------------	------	---------	-----	--------------	-----	------

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN HYDROBROMIDE

@	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb	DISC
@		EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb	DISC

DEFERASIROXTABLET; ORAL  
DEFERASIROX

>A>	AB	ALKEM LABS LTD	90MG	A210555	001	Mar 30, 2020	Mar	NEWA
>A>	AB		360MG	A210555	002	Mar 30, 2020	Mar	NEWA
	AB	AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb	CAHN
	AB		360MG	A210727	002	Dec 27, 2019	Feb	CAHN
	AB	CIPLA	90MG	A211852	001	Feb 11, 2020	Jan	NEWA
	AB		360MG	A211852	002	Feb 11, 2020	Jan	NEWA

DEFERIPRONESOLUTION; ORAL  
FERRIPROX

>D>	+	APOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018	Mar	CAHN
>D>	+	!	100MG/ML	N208030	001	Sep 09, 2015	Mar	CAHN
>A>	+	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Mar	CAHN
>A>	+	!	100MG/ML	N208030	001	Sep 09, 2015	Mar	CAHN



		TABLET;ORAL							
		FERRIPROX							
>D>	+	AOPHARMA INC	500MG	N021825	001	Oct 14, 2011	Mar	CAHN	
>D>	+		1GM	N021825	002	Jul 25, 2019	Mar	CAHN	
>A>	+	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CAHN	
>A>	+		1GM	N021825	002	Jul 25, 2019	Mar	CAHN	
>D>		<u>DELAVIRDINE MESYLATE</u>							
>D>		TABLET;ORAL							
>D>		RESCRIPTOR							
>D>	+	VIIV HLTHCARE	200MG	N020705	002	Jul 14, 1999	Mar	DISC	
>A>	+	@	200MG	N020705	002	Jul 14, 1999	Mar	DISC	
		<u>DESMOPRESSIN ACETATE</u>							
		INJECTABLE;INJECTION							
		DESMOPRESSIN ACETATE							
AP		UBI	0.004MG/ML	A210218	001	Feb 14, 2020	Feb	NEWA	
		<u>DESOGESTREL; ETHINYL ESTRADIOL</u>							
		TABLET;ORAL-28							
>D>		DESOGESTREL AND ETHINYL ESTRADIOL							
>D>	AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar	CTNA	
>A>		SIMLIYA							
>A>	AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar	CTNA	
		<u>DESOXIMETASONE</u>							
		CREAM;TOPICAL							
		DESOXIMETASONE							
>D>	@	CADILA	0.25%	A205620	001	Sep 28, 2018	Mar	CMFD	
>A>	AB		0.25%	A205620	001	Sep 28, 2018	Mar	CMFD	
	AB	COSETTE	0.25%	A209595	001	Mar 04, 2020	Feb	NEWA	
		<u>DESVENLAFAXINE SUCCINATE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		DESVENLAFAXINE SUCCINATE							
	@	MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Feb	DISC	
		<u>DEXAMETHASONE; TOBRAMYCIN</u>							
		SUSPENSION/DROPS;OPHTHALMIC							
		TOBRADEX ST							
	+	EYEVANCE	0.05%;0.3%	N050818	001	Feb 13, 2009	Feb	CAHN	
		<u>DEXMEDETOMIDINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		DEXMEDETOMIDINE							
AP		JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan	CTNA	
		DEXMEDETOMIDINE HYDROCHLORIDE							
AP		HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan	NEWA	
		<u>DEXMETHYLPHENIDATE HYDROCHLORIDE</u>							
		TABLET;ORAL							
		DEXMETHYLPHENIDATE HYDROCHLORIDE							
>A>	AB	BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Mar	NEWA	
>A>	AB		10MG	A209754	002	Mar 24, 2020	Mar	NEWA	
		<u>DEXTROAMPHETAMINE SULFATE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL							
		DEXTROAMPHETAMINE SULFATE							
	@	PII	5MG	A205077	001	Jun 21, 2019	Jan	DISC	
	@		10MG	A205077	002	Jun 21, 2019	Jan	DISC	
	@		15MG	A205077	003	Jun 21, 2019	Jan	DISC	
		<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>							
		SYRUP;ORAL							
		PROMETHAZINE DM							
>D>	@	SLATE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Mar	CMFD	
>A>	AA	!	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Mar	CMFD	
	@		15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Feb	CAHN	

## SYRUP;ORAL

## PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>D>	@ AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Mar	CMFD
>A>	AA	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Mar	CMFD
>D>	AA	HI TECH PHARMA	15MG/5ML;6.25MG/5ML	A040027	001	Jul 31, 1996	Mar DISC
>A>	@	15MG/5ML;6.25MG/5ML	A040027	001	Jul 31, 1996	Mar	DISC

DIAZEPAM

## SPRAY;NASAL

## VALTOCO

+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan	NEWA
+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan	NEWA
+	!	10MG/SPRAY	N211635	003	Jan 10, 2020	Jan	NEWA

DICLOFENAC POTASSIUM

## TABLET;ORAL

## CATAFLAM

+	@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan	CRLD
---	------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

## GEL;TOPICAL

## DICLOFENAC SODIUM

AB	ENCUBE	1%	A210986	001	Jan 27, 2020	Jan	NEWA
>D>	VOLTAREN						
>D>	AB	! GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CMS1
		TABLET, DELAYED RELEASE;ORAL					
		DICLOFENAC SODIUM					
>D>	@ ALLIED	50MG	A074986	001	Feb 26, 1999	Mar	CAHN
>D>	@	75MG	A074986	002	Feb 26, 1999	Mar	CAHN
>A>	@ MICRO LABS USA	50MG	A074986	001	Feb 26, 1999	Mar	CAHN
>A>	@	75MG	A074986	002	Feb 26, 1999	Mar	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

## TABLET, DELAYED RELEASE;ORAL

## DICLOFENAC SODIUM AND MISOPROSTOL

AB	YUNG SHIN PHARM	50MG;0.2MG	A205143	001	Feb 19, 2020	Feb	NEWA
AB		75MG;0.2MG	A205143	002	Feb 19, 2020	Feb	NEWA

DIETHYLPROPION HYDROCHLORIDE

## TABLET;ORAL

## TENUATE

>A>	+	@ NOSTRUM LABS INC	25MG	N011722	002		Mar CAHN
>D>	+	@ TEVA BRANDED PHARM	25MG	N011722	002		Mar CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		TENUATE DOSPAN					
>A>	+	@ NOSTRUM LABS INC	75MG	N012546	001		Mar CAHN
>D>	+	@ TEVA BRANDED PHARM	75MG	N012546	001		Mar CAHN

DIHYDROERGOTAMINE MESYLATE

## SPRAY, METERED;NASAL

## DIHYDROERGOTAMINE MESYLATE

AB	CUSTOPHARM INC	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Feb	NFTG
AB	!	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Feb CFTG

DISULFIRAM

## TABLET;ORAL

## DISULFIRAM

@	HIKMA	250MG	A202652	001	Feb 05, 2014	Feb	DISC
@		500MG	A202652	002	Feb 05, 2014	Feb	DISC

DIVALPROEX SODIUM

## CAPSULE, DELAYED REL PELLETS;ORAL

## DIVALPROEX SODIUM

AB	AJANTA PHARMA LTD	EQ 125MG VALPROIC ACID	A213181	001	Mar 02, 2020	Feb	NEWA
	@ MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan	DISC
		TABLET, DELAYED RELEASE;ORAL					
		DIVALPROEX SODIUM					
	@ MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan	DISC
	@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan	DISC
	@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan	DISC

DOCETAXELINJECTABLE; INJECTION  
DOCETAXEL

AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan	CMFD
AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan	CMFD
AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan	CMFD

DOFETILIDECAPSULE; ORAL  
DOFETILIDE

AB	MSN	0.125MG	A213220	001	Jan 29, 2020	Jan	NEWA
AB		0.25MG	A213220	002	Jan 29, 2020	Jan	NEWA
AB		0.5MG	A213220	003	Jan 29, 2020	Jan	NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL  
DONEPEZIL HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011	Mar	DISC
>A>		@	5MG	A090521	001	May 31, 2011	Mar	DISC
>D>	AB		10MG	A090521	002	May 31, 2011	Mar	DISC
>A>		@	10MG	A090521	002	May 31, 2011	Mar	DISC

DOXAZOSIN MESYLATETABLET; ORAL  
DOXAZOSIN MESYLATE

@	ANI PHARMS INC	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan	DISC
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan	DISC
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan	DISC
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan	DISC

DOXERCALCIFEROLINJECTABLE; INJECTION  
DOXERCALCIFEROL

AP	MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb	CAHN
AP	NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan	NEWA

DOXYCYCLINECAPSULE; ORAL  
DOXYCYCLINE

@	MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan	DISC
---	------------------	---------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATECAPSULE; ORAL  
DOXYCYCLINE HYCLATE

>A>	AB	ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020	Mar	NEWA
>A>	AB		EQ 100MG BASE	A212610	002	Mar 31, 2020	Mar	NEWA

TABLET; ORAL  
DOXYCYCLINE HYCLATE

AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb	NEWA	
>A>	AB	OAKLOCK LLC	EQ 100MG BASE	A210664	001	Mar 16, 2020	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL  
DORYX

>D>	+	@ MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar	CMFD
>A>	+		EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar	CMFD

AB	PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb	NEWA
----	--------------	--------------	---------	-----	--------------	-----	------

DRONABINOLCAPSULE; ORAL  
DRONABINOL

AB	ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan	NEWA
AB		5MG	A207421	002	Feb 07, 2020	Jan	NEWA
AB		10MG	A207421	003	Feb 07, 2020	Jan	NEWA

MARINOL

AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan	CAHN
AB	+	!	5MG	N018651	002	May 31, 1985	Jan	CAHN
AB	+		10MG	N018651	003	May 31, 1985	Jan	CAHN

SOLUTION; ORAL  
SYNDROS

+	!	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Feb	CAHN
---	---	---------	--------	---------	-----	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

	DROSPIRENONE AND ETHINYL ESTRADIOL							
AB	ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan	CAHN	

TABLET; ORAL-28

	DROSPIRENONE AND ETHINYL ESTRADIOL							
AB	HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan	NEWA	

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

>D>	AB	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Mar	DISC
>A>		@	EQ 20MG BASE	A207219	001	Aug 16, 2019	Mar	DISC
>D>	AB		EQ 30MG BASE	A207219	002	Aug 16, 2019	Mar	DISC
>A>		@	EQ 30MG BASE	A207219	002	Aug 16, 2019	Mar	DISC
>D>	AB		EQ 60MG BASE	A207219	003	Aug 16, 2019	Mar	DISC
>A>		@	EQ 60MG BASE	A207219	003	Aug 16, 2019	Mar	DISC

DUTASTERIDE

CAPSULE; ORAL

DUTASTERIDE

	@	ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan	DISC
	@	APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Feb	DISC
	@	HIKMA	0.5MG	A202204	001	Nov 23, 2015	Feb	DISC
>D>	@	PII	0.5MG	A208227	001	Jun 22, 2018	Mar	CAHN
>A>	@	STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018	Mar	CAHN

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

>D>	@	CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Mar	CAHN
>A>	@	CHARTWELL RX	1%	A076075	001	Nov 26, 2002	Mar	CAHN

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRIJARDY XR

+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan	NEWA	
+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan	NEWA	
+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan	NEWA	
+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan	NEWA	

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@	MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb	DISC
AB		ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb	NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

@	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan	DISC
@		1MG	A206226	002	Mar 26, 2019	Jan	DISC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>D>	@	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN
>A>	@	CHARTWELL RX	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN

EPLERENONE

TABLET; ORAL

EPLERENONE

AB	COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb	CAHN	
AB		50MG	A078482	002	Jul 30, 2008	Feb	CAHN	

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

>A>	AP	HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Mar	NEWA
>A>	AP		75MG/100ML	A207864	002	Mar 20, 2020	Mar	NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan	CAHN
----	-------------------	-----------------	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar	NFTG
>A>		EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar	NFTG
>A>		EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar	NFTG
	NEXIUM						
>D>	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar	CFTG
>A>	AB +	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar	CFTG
>D>	+	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar	CFTG
>A>	AB +	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar	CFTG
>D>	+	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar	CFTG
>A>	AB +!	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar	CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A204206	001	Feb 18, 2020	Feb	NEWA
AB		EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Feb	NEWA
	VIMOVO						
AB	+ HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Feb	CTEC
AB	+	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Feb	CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>A>	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar	NEWA
>A>		EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar	NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

>A>	+ @ BELCHER	24.65MG	N202342	001	Aug 06, 2013	Mar	CAHN
>A>	+ @	49.3MG	N202342	002	Aug 06, 2013	Mar	CAHN
>D>	+ @ R2 PHARMA LLC	24.65MG	N202342	001	Aug 06, 2013	Mar	CAHN
>D>	+ @	49.3MG	N202342	002	Aug 06, 2013	Mar	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

@ TEVA PHARMS USA 0.5MG;0.1MG

A200747	001	Mar 08, 2012	Jan	DISC
---------	-----	--------------	-----	------

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

@ MYLAN 0.75MG

A040359	001	Aug 26, 1999	Jan	DISC
---------	-----	--------------	-----	------

@ 1.5MG

A040359	002	Aug 26, 1999	Jan	DISC
---------	-----	--------------	-----	------

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ HIKMA 1MG

A091153	001	Apr 15, 2014	Feb	DISC
---------	-----	--------------	-----	------

@ 2MG

A091153	002	Apr 15, 2014	Feb	DISC
---------	-----	--------------	-----	------

@ 3MG

A091153	003	Apr 15, 2014	Feb	DISC
---------	-----	--------------	-----	------

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

AB	UPSHER SMITH LABS	25MG	A212417	001	Feb 19, 2020	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

+	AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020	Feb	NEWA
---	-------	-------------------------	---------	-----	--------------	-----	------

		TABLET;ORAL							
		BALCOLTRA							
		+! AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan	CHRS	
		+	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan	CRLD	
>D>		FAYOSIM							
>D>	AB	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar	DISC	
>A>		@	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar	DISC	
		TABLET;ORAL-28							
>D>		ELIFEMME							
>D>	AB	XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Mar	DISC	
>A>		@	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Mar	DISC	
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
		@ MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Feb	DISC	
		TABLET, CHEWABLE;ORAL							
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
>A>		+! EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020	Mar	NEWA	
		<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
		TABLET;ORAL							
		LOESTRIN 24 FE							
AB		+ TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan	CAHN	
		TABLET;ORAL-21							
		LOESTRIN 21 1.5/30							
AB		+ TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jan	CAHN	
		LOESTRIN 21 1/20							
AB		+ TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jan	CAHN	
		LOESTRIN FE 1.5/30							
AB		+! TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jan	CAHN	
		TABLET;ORAL-28							
		CHABELINA FE							
>A>	AB	NOVAST LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020	Mar	NEWA	
		LOESTRIN FE 1/20							
AB		+ TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jan	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
		@ MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb	DISC	
		TABLET, CHEWABLE;ORAL							
		FINZALA							
>A>	AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Mar	NEWA	
		<u>ETHOSUXIMIDE</u>							
		CAPSULE;ORAL							
		ETHOSUXIMIDE							
>A>	AB	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Mar	NEWA	
		<u>ETODOLAC</u>							
		TABLET;ORAL							
		ETODOLAC							
		@ TEVA	400MG	A075009	001	Nov 26, 1997	Feb	DISC	
		@	500MG	A075009	002	Dec 28, 1999	Feb	DISC	
		<u>ETOMIDATE</u>							
		INJECTABLE;INJECTION							
		ETOMIDATE							
		@ MYLAN LABS LTD	2MG/ML	A078289	001	Jan 02, 2009	Feb	DISC	
		<u>EXEMESTANE</u>							
		TABLET;ORAL							
		EXEMESTANE							
		@ MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jan	DISC	
>A>	AB	QILU	25MG	A213547	001	Apr 13, 2020	Mar	NEWA	
		<u>EZETIMIBE</u>							
		TABLET;ORAL							
		EZETIMIBE							
		@ MYLAN	10MG	A201790	001	Apr 26, 2019	Feb	DISC	
>D>	AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	Mar	DISC	
>A>		@	10MG	A078724	001	Jun 12, 2017	Mar	DISC	

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AB	!	AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan	CHRS
	@	MYLAN	20MG	A075704	001	Apr 16, 2001	Feb	DISC
>D>	AB	TEVA	20MG	A075311	001	Apr 16, 2001	Mar	DISC
>A>	@		20MG	A075311	001	Apr 16, 2001	Mar	DISC
>D>	AB		40MG	A075311	002	Apr 16, 2001	Mar	DISC
>A>	@		40MG	A075311	002	Apr 16, 2001	Mar	DISC
		PEPCID						
	+	@ VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Jan	DISC
	+	@	40MG	N019462	002	Oct 15, 1986	Jan	DISC

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB		ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan	CAHN
AB			134MG	A209504	002	Apr 30, 2018	Jan	CAHN
AB			200MG	A209504	003	Apr 30, 2018	Jan	CAHN
>D>	AB	MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013	Mar	DISC
>A>	@		43MG	A202579	001	Jan 10, 2013	Mar	DISC
>D>	AB		130MG	A202579	002	Jan 10, 2013	Mar	DISC
>A>	@		130MG	A202579	002	Jan 10, 2013	Mar	DISC

TABLET; ORAL

FENOFIBRATE

AB		ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan	NEWA
AB			160MG	A213252	002	Jan 17, 2020	Jan	NEWA
AB		APPCO	54MG	A210670	001	Sep 06, 2019	Jan	CAHN
AB			160MG	A210670	002	Sep 06, 2019	Jan	CAHN
>A>	AB	GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar	NEWA
AB			54MG	A210606	001	Aug 17, 2018	Jan	CMFD
>A>	AB		145MG	A211122	002	Mar 18, 2020	Mar	NEWA
AB			160MG	A210606	002	Aug 17, 2018	Jan	CMFD

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	!	HIKMA	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
----	---	---	-------	-------------------	---------	-----	--------------	-----	------

FERRIC DERISOMALTOSE

SOLUTION; INTRAVENOUS

MONOFERRIC

+	!	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan	NEWA
+	!		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan	NEWA
+	!		1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan	NEWA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION; INTRAVENOUS

TRIFERIC AVNU

>A>		+	!	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Mar	NEWA
-----	--	---	---	----------------------	-----------------------------------	---------	-----	--------------	-----	------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

@ DR REDDYS LABS LTD 4MG

@ 8MG

A204975	001	Aug 13, 2019	Feb	DISC
A204975	002	Aug 13, 2019	Feb	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

>D>	AB		BARR	30MG	A076191	001	Aug 31, 2005	Mar	DISC
>A>	@			30MG	A076191	001	Aug 31, 2005	Mar	DISC
>D>	AB			60MG	A076191	002	Aug 31, 2005	Mar	DISC
>A>	@			60MG	A076191	002	Aug 31, 2005	Mar	DISC
>D>	AB			180MG	A076191	003	Aug 31, 2005	Mar	DISC
>A>	@			180MG	A076191	003	Aug 31, 2005	Mar	DISC

FIDAXOMICINFOR SUSPENSION;ORAL  
DIFICID

+! CUBIST PHARMS LLC 40MG/ML N213138 001 Jan 24, 2020 Jan NEWA

FINASTERIDETABLET;ORAL  
FINASTERIDE>D> AB TEVA 1MG A076905 001 Nov 05, 2013 Mar DISC  
>A> @ 1MG A076905 001 Nov 05, 2013 Mar DISCFLUCONAZOLEFOR SUSPENSION;ORAL  
FLUCONAZOLE@ HIKMA 50MG/5ML A076246 001 Jul 29, 2004 Feb DISC  
@ 200MG/5ML A076246 002 Jul 29, 2004 Feb DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) A078764 001 Jan 30, 2012 Mar DISC  
>A> @ 200MG/100ML (2MG/ML) A078764 001 Jan 30, 2012 Mar DISC  
>D> AP 400MG/200ML (2MG/ML) A078764 002 Jan 30, 2012 Mar DISC  
>A> @ 400MG/200ML (2MG/ML) A078764 002 Jan 30, 2012 Mar DISC  
>D> AP ! HOSPIRA 200MG/100ML (2MG/ML) A076304 001 Jul 29, 2004 Mar DISC  
>A> @ 200MG/100ML (2MG/ML) A076304 001 Jul 29, 2004 Mar DISC  
>D> AP ! 400MG/200ML (2MG/ML) A076304 002 Jul 29, 2004 Mar DISC  
>A> @ 400MG/200ML (2MG/ML) A076304 002 Jul 29, 2004 Mar DISC  
>D> AP WOODWARD 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Mar DISC  
>A> @ 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Mar DISC  
>D> AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Mar DISC  
>A> @ 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Mar DISC

TABLET;ORAL

FLUCONAZOLE

@ MYLAN 50MG A076351 001 Jul 29, 2004 Jan DISC  
@ 100MG A076351 002 Jul 29, 2004 Jan DISC  
@ 150MG A076351 003 Jul 29, 2004 Jan DISC  
@ 200MG A076351 004 Jul 29, 2004 Jan DISC  
>D> AB TEVA 50MG A074681 001 Jul 29, 2004 Mar DISC  
>A> @ 50MG A074681 001 Jul 29, 2004 Mar DISC  
>D> AB 100MG A074681 002 Jul 29, 2004 Mar DISC  
>A> @ 100MG A074681 002 Jul 29, 2004 Mar DISC  
>D> AB 150MG A074681 003 Jul 29, 2004 Mar DISC  
>A> @ 150MG A074681 003 Jul 29, 2004 Mar DISC  
>D> AB 200MG A074681 004 Jul 29, 2004 Mar DISC  
>A> @ 200MG A074681 004 Jul 29, 2004 Mar DISCFLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP UNIV TX SW MEDCTR 20-200mCi/ML A210265 001 Feb 06, 2020 Jan NEWA

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

>D> @ APOTEX 0.029MG/SPRAY A077436 001 Aug 09, 2007 Mar CMFD  
>A> ! 0.029MG/SPRAY A077436 001 Aug 09, 2007 Mar CHRS  
>A> 0.029MG/SPRAY A077436 001 Aug 09, 2007 Mar CMFDFLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB CADILA 0.1% A208989 001 Feb 10, 2020 Feb CAHN  
AB ZYDUS PHARMS 0.1% A208989 001 Feb 10, 2020 Jan NEWA

SOLUTION;TOPICAL

FLUOCINONIDE

>D> AT TEVA 0.05% A072511 001 Feb 07, 1989 Mar DISC  
>A> @ 0.05% A072511 001 Feb 07, 1989 Mar DISC



FLUOROURACILSOLUTION; TOPICAL  
FLUOROURACIL

>D>	AT	TARO	5%	A076526	002	Nov 05, 2003	Mar	CHRS
>A>	AT	!	5%	A076526	002	Nov 05, 2003	Mar	CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002	Mar	DISC
>A>		@	EQ 10MG BASE	A074803	002	Jan 30, 2002	Mar	DISC
>D>	AB1		EQ 20MG BASE	A074803	001	Aug 02, 2001	Mar	DISC
>A>		@	EQ 20MG BASE	A074803	001	Aug 02, 2001	Mar	DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>D>		@ AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Mar	CMFD
>A>	AA		EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Mar	CMFD

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020	Mar	NEWA
>A>	AB		EQ 20MG BASE	A213286	002	Apr 08, 2020	Mar	NEWA
>D>	AB	G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Mar	DISC
>A>		@	EQ 60MG BASE	A212191	001	Jul 05, 2019	Mar	DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

>D>	AB	SANDOZ	1MG	A089586	002	Oct 16, 1987	Mar	DISC
>A>		@	1MG	A089586	002	Oct 16, 1987	Mar	DISC
>D>	AB		2.5MG	A089586	003	Oct 16, 1987	Mar	DISC
>A>		@	2.5MG	A089586	003	Oct 16, 1987	Mar	DISC
>D>	AB		5MG	A089586	004	Oct 16, 1987	Mar	DISC
>A>		@	5MG	A089586	004	Oct 16, 1987	Mar	DISC
>D>	AB		10MG	A089586	001	Oct 16, 1987	Mar	DISC
>A>		@	10MG	A089586	001	Oct 16, 1987	Mar	DISC

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

>A>		+ TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Mar	NEWA
>A>		+ !	0.113MG/INH	N208798	005	Feb 20, 2020	Mar	NEWA
>A>		+ !	0.232MG/INH	N208798	006	Feb 20, 2020	Mar	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>D>	AB	TEVA	25MG	A075893	001	Sep 10, 2002	Mar	DISC
>A>		@	25MG	A075893	001	Sep 10, 2002	Mar	DISC
>D>	AB		50MG	A075893	002	Sep 10, 2002	Mar	DISC
>A>		@	50MG	A075893	002	Sep 10, 2002	Mar	DISC
>D>	AB		100MG	A075893	003	Sep 10, 2002	Mar	DISC
>A>		@	100MG	A075893	003	Sep 10, 2002	Mar	DISC

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP		X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019	Jan	CAHN
AP		XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019	Feb	CAHN

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FULVESTRANT

AO		CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020	Jan	NEWA
----	--	-------------------	---------	---------	-----	--------------	-----	------

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

@ AVET

@

20MG

40MG

N018413 001 Nov 30, 1983 Jan DISC

N018413 002 Nov 30, 1983 Jan DISC

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		CSPC OUYI	100MG	A075477	001	Mar 23, 2005	Jan CMFD
AB			300MG	A075477	002	Mar 23, 2005	Jan CMFD
AB			400MG	A075477	003	Mar 23, 2005	Jan CMFD
>D>	AB	TEVA PHARMS	100MG	A075435	001	Oct 08, 2004	Mar DISC
>A>		@	100MG	A075435	001	Oct 08, 2004	Mar DISC
>D>	AB		300MG	A075435	002	Oct 08, 2004	Mar DISC
>A>		@	300MG	A075435	002	Oct 08, 2004	Mar DISC
>D>	AB		400MG	A075435	003	Oct 08, 2004	Mar DISC
>A>		@	400MG	A075435	003	Oct 08, 2004	Mar DISC

TABLET;ORAL

GABAPENTIN

>D>	AB	MYLAN PHARMS INC	600MG	A090335	001	Jun 01, 2010	Mar DISC
>A>		@	600MG	A090335	001	Jun 01, 2010	Mar DISC
>D>	AB		800MG	A090335	002	Jun 01, 2010	Mar DISC
>A>		@	800MG	A090335	002	Jun 01, 2010	Mar DISC
>D>	AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Mar DISC
>A>		@	600MG	A205807	001	Mar 10, 2017	Mar DISC
>D>	AB		800MG	A205807	002	Mar 10, 2017	Mar DISC
>A>		@	800MG	A205807	002	Mar 10, 2017	Mar DISC
		GRALISE					
BX	+	ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CAHN
BX	+		600MG	N022544	002	Jan 28, 2011	Jan CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

@ HIKMA

EQ 4MG BASE

A077608 001 Feb 11, 2009 Feb DISC

@

EQ 8MG BASE

A077608 002 Feb 11, 2009 Feb DISC

@

EQ 12MG BASE

A077608 003 Feb 11, 2009 Feb DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

@ APOTEX

200MG/5.26ML (38MG/ML)

A206776 001 May 23, 2017 Feb DISC

@

1GM/26.3ML (38MG/ML)

A206776 002 May 23, 2017 Feb DISC

@

2GM/52.6ML (38MG/ML)

A206776 003 May 23, 2017 Feb DISC

>D>	AP	MYLAN LABS LTD	EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Mar DISC
>A>		@	EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Mar DISC
	AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Jan CMFD
	AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Jan CMFD
>D>	AP	TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Mar DISC
>A>		@	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Mar DISC
>D>	AP		EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Mar DISC
>A>		@	EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Mar DISC

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		CADILA	600MG	A204189	001	Aug 28, 2018	Feb CAHN
		@ TEVA	600MG	A074256	001	Oct 31, 1993	Feb DISC

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

>D>	AP	HOSPIRA	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986	Mar DISC
>A>		@	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986	Mar DISC

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

@ MYLAN

1.5MG

A074792 001 Jun 26, 1998 Jan DISC

@

3MG

A074792 002 Jun 26, 1998 Jan DISC

@

6MG

A074792 003 Aug 17, 1999 Jan DISC

GLYCOPYRROLATE

		INJECTABLE; INJECTION						
		GLYCOPYRROLATE						
AP		RICONPHARMA LLC	0.2MG/ML	A210083	001	Feb 21, 2020	Feb	NEWA
		POWDER; INHALATION						
		SEEBRI						
>A>	+	@ NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar	CAHN
>D>	+	! SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar	DISC
>A>	+	@	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar	DISC

GLYCOPYRROLATE; INDACATEROL MALEATE

		POWDER; INHALATION						
		UTIBRON						
>A>	+	@ NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	CAHN
>D>	+	! SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	DISC
>A>	+	@	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	DISC

GRANISETRON HYDROCHLORIDE

		INJECTABLE; INJECTION						
		GRANISETRON HYDROCHLORIDE						
>D>	AP	MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Mar	DISC
>A>		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Mar	DISC
		TABLET; ORAL						
		GRANISETRON HYDROCHLORIDE						
		@ MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan	DISC

HALCINONIDE

		SOLUTION; TOPICAL						
		HALOG						
>D>		@ SUN PHARM INDS INC	0.1%	N017823	001		Mar	CMFD
>A>		!	0.1%	N017823	001		Mar	CMFD

HALOPERIDOL LACTATE

		INJECTABLE; INJECTION						
		HALOPERIDOL						
>D>	AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Mar	DISC
>A>		@	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Mar	DISC

HEPARIN SODIUM

		INJECTABLE; INJECTION								
		HEPARIN SODIUM								
AP		NANJING KING-FRIEND	20,000 UNITS/ML	A211004	001	Feb 24, 2020	Feb	NEWA		
		HEPARIN SODIUM PRESERVATIVE FREE								
>D>		+	! FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	CTEC	
>A>	AP	+	!	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	CTEC	
>A>	AP			NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Mar	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

		TABLET; ORAL							
		HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE							
AA		!	NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011	Jan	CHRS
		TUSSIGON							
		@ KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Jan	DISC	

HYDRALAZINE HYDROCHLORIDE

		INJECTABLE; INJECTION						
		HYDRALAZINE HYDROCHLORIDE						
AP		XGEN PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
		TABLET; ORAL						
		HYDRALAZINE HYDROCHLORIDE						
		@ STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Jan	DISC

HYDROCHLOROTHIAZIDE

		CAPSULE; ORAL						
		HYDROCHLOROTHIAZIDE						
>D>	AB	IVAX SUB TEVA PHARMS	12.5MG	A077005	001	Jul 13, 2005	Mar	DISC
>A>		@	12.5MG	A077005	001	Jul 13, 2005	Mar	DISC
		TABLET; ORAL						
		HYDROCHLOROTHIAZIDE						
		@ MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007	Jan	DISC

## TABLET;ORAL

## HYDROCHLOROTHIAZIDE

@	50MG	A040735	003	Jan 23, 2007	Jan DISC
---	------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

## TABLET;ORAL

## LISINAPRIL AND HYDROCHLOROTHIAZIDE

@	COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004	Feb CAHN
@		12.5MG;20MG	A076674	002	Oct 05, 2004	Feb CAHN
@		25MG;20MG	A076674	003	Oct 05, 2004	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>D>	AB	UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	Mar DISC
>A>		@	12.5MG;20MG	A208847	001	Sep 17, 2019	Mar DISC
>D>	AB		12.5MG;40MG	A208847	003	Sep 17, 2019	Mar DISC
>A>		@	12.5MG;40MG	A208847	003	Sep 17, 2019	Mar DISC
>D>	AB		25MG;40MG	A208847	002	Sep 17, 2019	Mar DISC
>A>		@	25MG;40MG	A208847	002	Sep 17, 2019	Mar DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## CAPSULE;ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	25MG;37.5MG	A208358	001	Feb 11, 2019	Feb CAHN	
>D>		@	CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Mar CAHN
>A>		@	CHARTWELL RX	25MG;50MG	A073191	001	Jul 31, 1991	Mar CAHN
>D>	AB		DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999	Mar DISC
>A>		@		25MG;37.5MG	A075052	001	Jun 18, 1999	Mar DISC

## TABLET;ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>D>	AB		PLIVA	25MG;37.5MG	A074026	001	Apr 26, 1996	Mar DISC
>A>		@		25MG;37.5MG	A074026	001	Apr 26, 1996	Mar DISC

HYDROCODONE BITARTRATE

## CAPSULE, EXTENDED RELEASE;ORAL

## HYDROCODONE BITARTRATE

AB		ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan NFTG
AB			15MG	A206986	002	Jan 21, 2020	Jan NFTG
AB			20MG	A206986	003	Jan 21, 2020	Jan NFTG
AB			30MG	A206986	004	Jan 21, 2020	Jan NFTG
AB			40MG	A206986	005	Jan 21, 2020	Jan NFTG
AB			50MG	A206986	006	Jan 21, 2020	Jan NFTG
		ZOHYDRO ER					
AB	+!	PERSION	10MG	N202880	001	Oct 25, 2013	Jan CFTG
AB	+		15MG	N202880	002	Oct 25, 2013	Jan CFTG
AB	+		20MG	N202880	003	Oct 25, 2013	Jan CFTG
AB	+		30MG	N202880	004	Oct 25, 2013	Jan CFTG
AB	+		40MG	N202880	005	Oct 25, 2013	Jan CFTG
AB	+		50MG	N202880	006	Oct 25, 2013	Jan CFTG

HYDROCORTISONE

## ENEMA;RECTAL

## HYDROCORTISONE

>D>								
>D>	AB		TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994	Mar DISC
>A>			@	100MG/60ML	A074171	001	May 27, 1994	Mar DISC

## OINTMENT;TOPICAL

## HYDROCORTISONE

>D>	AT		ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982	Mar DISC
>A>			@	1%	A087796	001	Oct 13, 1982	Mar DISC

## TABLET;ORAL

## HYDROCORTISONE

AB		STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017	Feb CAHN
AB			10MG	A207029	002	Apr 27, 2017	Feb CAHN
AB			20MG	A207029	003	Apr 27, 2017	Feb CAHN

HYDROCORTISONE VALERATE

## OINTMENT;TOPICAL

## HYDROCORTISONE VALERATE

AB		COSETTE	0.2%	A211764	001	Mar 04, 2020	Feb NEWA
----	--	---------	------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDEINJECTABLE; INJECTION  
DILAUDID

	+!	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Jan	NEWA
		HYDROMORPHONE HYDROCHLORIDE						
>D>	AP	BARR	10MG/ML	A076444	001	Apr 25, 2003	Mar	DISC
>A>		@	10MG/ML	A076444	001	Apr 25, 2003	Mar	DISC
		TABLET; ORAL						
		HYDROMORPHONE HYDROCHLORIDE						
AB		NOSTRUM LABS INC	8MG	A076723	001	Oct 18, 2005	Feb	CAHN

HYDROXYCHLOROQUINE SULFATETABLET; ORAL  
HYDROXYCHLOROQUINE SULFATE

>A>	AB	ACCORD HLTHCARE	200MG	A213342	001	Apr 07, 2020	Mar	NEWA
>A>	AB	APPCO	200MG	A210441	001	May 01, 2018	Mar	CAHN
>D>		@ LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Mar	CMFD
>A>	AB		200MG	A210959	001	Jan 15, 2019	Mar	CMFD
>D>		@ LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Mar	CMFD
>A>	AB		200MG	A210543	001	Jul 06, 2018	Mar	CMFD
>D>	AB	TWI PHARMS	200MG	A210441	001	May 01, 2018	Mar	CAHN

HYDROXYPROGESTERONE CAPROATESOLUTION; INTRAMUSCULAR  
HYDROXYPROGESTERONE CAPROATE

		@ AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC
AP1			1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan	CMS1

HYDROXYUREACAPSULE; ORAL  
HYDROXYUREA

>A>	AB	LEADING PHARMA LLC	500MG	A213438	001	Apr 08, 2020	Mar	NEWA
-----	----	--------------------	-------	---------	-----	--------------	-----	------

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS  
IBUPROFEN LYSINE

AP		XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN
----	--	-------------	------------------------------------	---------	-----	--------------	-----	------

ICATIBANT ACETATEINJECTABLE; SUBCUTANEOUS  
ICATIBANT ACETATE

AP		JIANGSU HANSOH PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211021	001	Mar 09, 2020	Feb	NEWA
----	--	----------------------	------------------------------------	---------	-----	--------------	-----	------

IMATINIB MESYLATETABLET; ORAL  
IMATINIB MESYLATE

>A>	AB	ZYDUS PHARMS	EQ 100MG BASE	A210658	001	Apr 08, 2020	Mar	NEWA
>A>	AB		EQ 400MG BASE	A210658	002	Apr 08, 2020	Mar	NEWA

INDACATEROL MALEATEPOWDER; INHALATION  
ARCAPTA NEOHALER

>A>		+ @ NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	CAHN
>D>		+! SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	DISC
>A>		+ @	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	DISC

INDAPAMIDETABLET; ORAL  
INDAPAMIDE

AB		ANI PHARMS INC	1.25MG	A075201	001	Dec 04, 1998	Jan	CAHN
AB			2.5MG	A075201	002	Dec 04, 1998	Jan	CAHN

INDINAVIR SULFATECAPSULE; ORAL  
CRIKIVAN

>D>		+ MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996	Mar	DISC
>A>		+ @	EQ 200MG BASE	N020685	003	Mar 13, 1996	Mar	DISC

INDOMETHACINCAPSULE;ORAL  
INDOMETHACIN

AB	HERITAGE	25MG	N018851	001	May 18, 1984	Jan	CAHN
AB		50MG	N018851	002	May 18, 1984	Jan	CAHN
>D>	AB	HERITAGE PHARMA	A070756	001	Feb 12, 1986	Mar	DISC
>A>	@	50MG	A070756	001	Feb 12, 1986	Mar	DISC

IPRATROPIUM BROMIDESPRAY, METERED;NASAL  
IPRATROPIUM BROMIDE

AB	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD
----	------------	---------------	---------	-----	--------------	-----	------

IRBESARTANTABLET;ORAL  
IRBESARTAN

@	HIKMA	75MG	A090201	001	Oct 15, 2012	Feb	DISC
@		150MG	A090201	002	Oct 15, 2012	Feb	DISC
@		300MG	A090201	003	Oct 15, 2012	Feb	DISC

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE;ORAL  
ISOSORBIDE MONONITRATE

@	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Feb	DISC
@		60MG	A076813	001	Jan 07, 2005	Feb	DISC

ITRACONAZOLESOLUTION;ORAL  
ITRACONAZOLE

@	APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Feb	DISC
---	--------	---------	---------	-----	--------------	-----	------

IVERMECTINCREAM;TOPICAL  
IVERMECTIN

>A>	AB	PERRIGO UK FINCO	1%	A210225	001	Apr 13, 2020	Mar	NEWA
-----	----	------------------	----	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINETABLET;ORAL  
KETOROLAC TROMETHAMINE

AB	MYLAN	10MG	A074761	001	May 16, 1997	Feb	CHRS
AB	! TEVA	10MG	A074754	001	May 16, 1997	Feb	CHRS

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTION  
NORMODYNE

+	@ SCHERING	5MG/ML	N018686	001	Aug 01, 1984	Jan	CRLD
---	------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL  
LABETALOL HYDROCHLORIDE

AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb	CMFD
AB		200MG	A074787	002	Aug 03, 1998	Feb	CMFD

LACTITOLFOR SOLUTION;ORAL  
PIZENSY

+	! BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020	Feb	NEWA
+		10GM/PACKET	N211281	001	Feb 12, 2020	Feb	NEWA

LAMOTRIGINETABLET;ORAL  
LAMOTRIGINE

>D>	AB	MYLAN	25MG	A077420	001	Jan 27, 2009	Mar	DISC
>A>	@	25MG	A077420	001	Jan 27, 2009	Mar	DISC	
>D>	AB	100MG	A077420	002	Jan 27, 2009	Mar	DISC	
>A>	@	100MG	A077420	002	Jan 27, 2009	Mar	DISC	
>D>	AB	150MG	A077420	003	Jan 27, 2009	Mar	DISC	
>A>	@	150MG	A077420	003	Jan 27, 2009	Mar	DISC	
>D>	AB	200MG	A077420	004	Jan 27, 2009	Mar	DISC	
>A>	@	200MG	A077420	004	Jan 27, 2009	Mar	DISC	

TABLET, EXTENDED RELEASE;ORALLAMOTRIGINE

>A>	AB	DR REDDYS LABS LTD	250MG	A202383	006	Sep 06, 2018	Mar	NEWA
>A>	AB	ZYDUS PHARMS	25MG	A207763	001	Apr 01, 2020	Mar	NEWA
>A>	AB		50MG	A207763	002	Apr 01, 2020	Mar	NEWA
>A>	AB		100MG	A207763	003	Apr 01, 2020	Mar	NEWA
>A>	AB		200MG	A207763	004	Apr 01, 2020	Mar	NEWA
>A>	AB		250MG	A207763	005	Apr 01, 2020	Mar	NEWA
>A>	AB		300MG	A207763	006	Apr 01, 2020	Mar	NEWA

LASMIDITAN SUCCINATE

## TABLET;ORAL

## REYVOW

+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA
+	!	100MG	N211280	002	Jan 31, 2020	Jan	NEWA

LATANOPROST

## SOLUTION/DROPS;OPHTHALMIC

## LATANOPROST

>D>	AT	AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Mar	DISC
>A>		@	0.005%	A206519	001	Sep 03, 2019	Mar	DISC

LEFLUNOMIDE

## TABLET;ORAL

## LEFLUNOMIDE

AB		LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA
AB			20MG	A211863	002	Feb 04, 2020	Jan	NEWA

LEUCOVORIN CALCIUM

## TABLET;ORAL

## LEUCOVORIN CALCIUM

>D>		@ EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	Mar	CMFD
>A>	AB		EQ 5MG BASE	A074544	001	Aug 28, 1997	Mar	CMFD
>D>		@	EQ 25MG BASE	A074544	002	Aug 28, 1997	Mar	CMFD
>A>	AB		EQ 25MG BASE	A074544	002	Aug 28, 1997	Mar	CMFD

LEVETIRACETAM

## INJECTABLE;INTRAVENOUS

## LEVETIRACETAM

AP		XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
----	--	-------------	----------------------	---------	-----	--------------	-----	------

## TABLET;ORAL

## LEVETIRACETAM

>D>	AB	APOTEX INC	250MG	A078869	001	Mar 13, 2009	Mar	CAHN
>D>	AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
>D>	AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
>D>	AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN
>A>	AB	VIWIT PHARM	250MG	A078869	001	Mar 13, 2009	Mar	CAHN
>A>	AB		250MG	A078869	001	Mar 13, 2009	Mar	CAHN
>A>	AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
>A>	AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
>A>	AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
>A>	AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
>A>	AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN
>A>	AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

## SOLUTION;ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

@	APOTEX	2.5MG/5ML	A202915	001	Aug 21, 2014	Feb	DISC
---	--------	-----------	---------	-----	--------------	-----	------

## TABLET;ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

@	APOTEX	5MG	A203027	001	Feb 13, 2015	Feb	DISC
---	--------	-----	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM

## POWDER;INTRAVENOUS

## LEVOTHYROXINE SODIUM

>A>	AP	DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Mar	NEWA
-----	----	-----------	-------------	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL  
THYRO-TABS

AB2, +	ALVOGEN	0.3MG	N021116	009	Oct 24, 2002	Jan	CHRS
AB4							

LIDOCAINEOINTMENT;TOPICAL  
LIDOCAINE

>A>	AT	MACLEODS PHARMS LTD	5%	A211697	001	Mar 16, 2020	Mar	NEWA
>D>	AT	SUNGEN PHARMA	5.0%	A212486	001	Oct 17, 2019	Mar	CPOT
>A>		@	5%	A212486	001	Oct 17, 2019	Mar	DISC
>A>	AT		5%	A212486	001	Oct 17, 2019	Mar	CPOT

LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION  
LIDOCAINE HYDROCHLORIDE

>D>		@ WEST-WARD PHARMS INT	1%	A080407	001		Mar	CMFD
>A>	AP		1%	A080407	001		Mar	CMFD
>D>		@	2%	A080407	002		Mar	CMFD
>A>	AP		2%	A080407	002		Mar	CMFD
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
>D>		@ WEST-WARD PHARMS INT	1%	A084625	001		Mar	CMFD
>A>	AP		1%	A084625	001		Mar	CMFD
>D>		@	2%	A084625	002		Mar	CMFD
>A>	AP		2%	A084625	002		Mar	CMFD

LINCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION  
LINCOMYCIN

AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

LIOETHYRONINE SODIUMINJECTABLE;INJECTION  
LIOETHYRONINE SODIUM

AP		XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb	CAHN
----	--	-------------	-------------------	---------	-----	--------------	-----	------

TABLET;ORAL

LIOETHYRONINE SODIUM

AB		SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
AB			EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
AB			EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD

LISINAPRILTABLET;ORAL  
LISINAPRIL

AB		COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb	CAHN
AB			5MG	A076102	002	Sep 30, 2002	Feb	CAHN
AB			10MG	A076102	003	Sep 30, 2002	Feb	CAHN
AB			20MG	A076102	004	Sep 30, 2002	Feb	CAHN
AB			30MG	A076102	005	Sep 30, 2002	Feb	CAHN
AB			40MG	A076102	006	Sep 30, 2002	Feb	CAHN

LITHIUM CARBONATECAPSULE;ORAL  
LITHIUM CARBONATE

AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
AB	+		300MG	N017812	001		Jan	CAHN
AB	+	!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN
		@ MYLAN	150MG	A076243	002	Feb 24, 2003	Jan	DISC
		@	300MG	A076243	001	Jun 27, 2002	Jan	DISC

LITHIUM CITRATESYRUP;ORAL  
LITHIUM CITRATE

AA	+	!	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001	Jan	CAHN
----	---	---	-------	------------------------	---------	-----	-----	------



LORAZEPAMTABLET; ORAL  
LORAZEPAM

>D>	AB	MYLAN	0.5MG	A077657	001	Mar 16, 2006	Mar	DISC
>A>		@	0.5MG	A077657	001	Mar 16, 2006	Mar	DISC
>D>	AB		1MG	A077657	002	Mar 16, 2006	Mar	DISC
>A>		@	1MG	A077657	002	Mar 16, 2006	Mar	DISC
>D>	AB		2MG	A077657	003	Mar 16, 2006	Mar	DISC
>A>		@	2MG	A077657	003	Mar 16, 2006	Mar	DISC

LORCASERIN HYDROCHLORIDETABLET; ORAL  
BELVIQ

+ @	EISAI INC	10MG	N022529	001	Jun 27, 2012	Feb	DISC
-----	-----------	------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL  
BELVIQ XR

+ @	EISAI INC	20MG	N208524	001	Jul 15, 2016	Feb	DISC
-----	-----------	------	---------	-----	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

@	HIKMA	25MG	A077459	001	Oct 06, 2010	Feb	DISC
---	-------	------	---------	-----	--------------	-----	------

@		50MG	A077459	002	Oct 06, 2010	Feb	DISC
---	--	------	---------	-----	--------------	-----	------

@		100MG	A077459	003	Oct 06, 2010	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	COREPHARMA	10MG	A077748	001	Feb 28, 2007	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

AB		20MG	A077748	002	Feb 28, 2007	Feb	CAHN
----	--	------	---------	-----	--------------	-----	------

AB		40MG	A077748	003	Feb 28, 2007	Feb	CAHN
----	--	------	---------	-----	--------------	-----	------

MAZINDOL

TABLET; ORAL

SANOREX

+ @	NOVARTIS	1MG	N017247	001		Jan	CAHN
-----	----------	-----	---------	-----	--	-----	------

+ @		2MG	N017247	002		Jan	CAHN
-----	--	-----	---------	-----	--	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Jan	DISC
---	------------------	--------	---------	-----	--------------	-----	------

@		25MG	A202640	002	Sep 17, 2012	Jan	DISC
---	--	------	---------	-----	--------------	-----	------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

!	BARR	250MG	A076392	001	Dec 29, 2003	Feb	CTEC
---	------	-------	---------	-----	--------------	-----	------

@	HIKMA	250MG	A076523	001	Oct 01, 2004	Feb	DISC
---	-------	-------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@	HIKMA	40MG/ML	A075997	001	Feb 15, 2002	Feb	DISC
---	-------	---------	---------	-----	--------------	-----	------

AB	!	PAR PHARM	40MG/ML	A075671	001	Jul 25, 2001	Feb	CHRS
----	---	-----------	---------	---------	-----	--------------	-----	------

MELOXICAM

SOLUTION; INTRAVENOUS

ANJESO

+!	BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020	Feb	NEWA
----	--------	-------------------	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Feb	NEWA
----	--------------------	-------------------	---------	-----	--------------	-----	------

@	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Feb	DISC
---	----------------------	-------------------	---------	-----	--------------	-----	------

@	TWI PHARMS	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Jan	DISC
---	------------	-------------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS

EVOMELA

>D>	AP	+!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CTEC
-----	----	----	----------	-------------------	---------	-----	--------------	-----	------

>A>		+!		EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CTEC
-----	--	----	--	-------------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS  
EVOMELA

AP	+	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Feb CFTG	
MELPHALAN HYDROCHLORIDE							
>D>	AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Mar DISC
>A>	@	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Mar DISC	
AP		EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Feb NFTG	

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
MEMANTINE HYDROCHLORIDE

AB	ANI PHARMS INC	7MG	A205365	001	Feb 28, 2020	Feb NEWA
AB		14MG	A205365	002	Feb 28, 2020	Feb NEWA
AB		21MG	A205365	003	Feb 28, 2020	Feb NEWA
AB		28MG	A205365	004	Feb 28, 2020	Feb NEWA

## TABLET; ORAL

## MEMANTINE HYDROCHLORIDE

>D>	@	APOTEX INC	5MG	A090244	001	Jul 11, 2018	Mar CAHN
>D>	@		10MG	A090244	002	Jul 11, 2018	Mar CAHN
>A>	@	CHARTWELL	5MG	A090244	001	Jul 11, 2018	Mar CAHN
>A>	@		10MG	A090244	002	Jul 11, 2018	Mar CAHN
AB		HIKMA PHARMS	5MG	A208173	001	Feb 28, 2020	Feb NEWA
AB			10MG	A208173	002	Feb 28, 2020	Feb NEWA
>A>	AB	NINGBO	5MG	A212947	001	Apr 03, 2020	Mar NEWA
>A>	AB		10MG	A212947	002	Apr 03, 2020	Mar NEWA

MEPERIDINE HYDROCHLORIDE

## TABLET; ORAL

## MEPERIDINE HYDROCHLORIDE

AA	!	EPIC PHARMA	50MG	A040331	001	May 28, 1999	Feb CHRS
AA	!		100MG	A040331	002	May 28, 1999	Feb CHRS
	@	HIKMA	50MG	A040110	001	Mar 12, 1997	Feb DISC
	@		100MG	A040110	002	Mar 12, 1997	Feb DISC

MESALAMINE

## SUPPOSITORY; RECTAL

## MESALAMINE

>A>	AB	ANNORA PHARMA	1GM	A213377	001	Mar 19, 2020	Mar NEWA
AB		ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan NEWA

METAXALONE

## TABLET; ORAL

## METAXALONE

>D>		MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Mar CTEC
>A>	AB		400MG	A040486	001	Feb 27, 2015	Mar CTEC
>A>	AB	SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020	Mar NEWA

METFORMIN HYDROCHLORIDE

## SOLUTION; ORAL

## METFORMIN HYDROCHLORIDE

AB		SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb NFTG
RIOMET							
AB	+	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb CFTG
	+		500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN

## TABLET; ORAL

## METFORMIN HYDROCHLORIDE

>D>	AB	HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Mar DISC
>A>	@		500MG	A075978	001	Jan 25, 2002	Mar DISC
>D>	AB		850MG	A075978	002	Jan 25, 2002	Mar DISC
>A>	@		850MG	A075978	002	Jan 25, 2002	Mar DISC
>D>	AB		1GM	A075978	003	Nov 05, 2002	Mar DISC
>A>	@		1GM	A075978	003	Nov 05, 2002	Mar DISC
	@	MYLAN	500MG	A075976	001	Jan 24, 2002	Jan DISC
	@		850MG	A075976	002	Jan 24, 2002	Jan DISC
	@		1GM	A075976	003	Jan 24, 2002	Jan DISC

## TABLET, EXTENDED RELEASE; ORAL

## METFORMIN HYDROCHLORIDE

>A>	AB2	AJANTA PHARMA LTD	500MG	A213651	001	Apr 09, 2020	Mar NEWA
>A>	AB2		1GM	A213651	002	Apr 09, 2020	Mar NEWA

METHADONE HYDROCHLORIDE

## TABLET; ORAL

## METHADONE HYDROCHLORIDE

>D>	AA	ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Mar CAHN
>D>	AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
>A>	AA	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Mar CAHN
>A>	AA		5MG	A210484	001	Aug 02, 2018	Mar CAHN
>A>	AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
>A>	AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
>A>	AA	VISTAPHARM	10MG	A204166	001	Mar 16, 2020	Mar NEWA

METHOCARBAMOL

## TABLET; ORAL

## METHOCARBAMOL

@	HIKMA INTL PHARMS	500MG	A085159	001			Feb DISC
@		750MG	A085123	001			Feb DISC

METHOTREXATE SODIUM

## INJECTABLE; INJECTION

## METHOTREXATE SODIUM PRESERVATIVE FREE

@	MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Jan DISC
@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Jan DISC
@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Jan DISC
	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Jan CTEC

## TABLET; ORAL

## METHOTREXATE SODIUM

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A213343	001	Jan 24, 2020	Jan NEWA	
>D>	AB	+! DAVA PHARMS INC	EQ 2.5MG BASE	N008085	002	Mar DISC	
>A>	AB	+ @	EQ 2.5MG BASE	N008085	002	Mar DISC	
AB	EUGIA PHARMA	EQ 2.5MG BASE	A210454	001	Jan 30, 2020	Jan NEWA	
>D>	AB	HIKMA	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Mar CHRS
>A>	AB	!	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Mar CHRS

METHYLPHENIDATE HYDROCHLORIDE

## SOLUTION; ORAL

## METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020	Mar NEWA
>A>	AA		10MG/5ML	A211647	002	Mar 30, 2020	Mar NEWA
>A>	AA	PATRIN PHARMA INC	5MG/5ML	A210764	001	Apr 10, 2020	Mar NEWA
>A>	AA		10MG/5ML	A210764	002	Apr 10, 2020	Mar NEWA

## TABLET, EXTENDED RELEASE; ORAL

## METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018	Mar DISC
>A>	AB	@	18MG	A076772	001	Mar 22, 2018	Mar DISC
>D>	AB		27MG	A076772	002	Mar 22, 2018	Mar DISC
>A>	AB	@	27MG	A076772	002	Mar 22, 2018	Mar DISC
>D>	AB		36MG	A076772	003	Mar 22, 2018	Mar DISC
>A>	AB	@	36MG	A076772	003	Mar 22, 2018	Mar DISC
>D>	AB		54MG	A076655	001	Mar 21, 2018	Mar DISC
>A>	AB	@	54MG	A076655	001	Mar 21, 2018	Mar DISC

METHYLPREDNISOLONE

## TABLET; ORAL

## METHYLPREDNISOLONE

>D>	AB	DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar DISC
>A>	AB	@	4MG	A088497	001	Feb 21, 1984	Mar DISC

METOPROLOL SUCCINATE

## TABLET, EXTENDED RELEASE; ORAL

## METOPROLOL SUCCINATE

>D>	AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar DISC
>A>	AB	@	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar DISC
>D>	AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar DISC
>A>	AB	@	EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar DISC
>D>	AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar DISC
>A>	AB	@	EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar DISC
>D>	AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar DISC
>A>	AB	@	EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar DISC
		@ ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan DISC

TABLET, EXTENDED RELEASE;ORAL  
METOPROLOL SUCCINATE

	@	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan	DISC	
	@	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan	DISC	
>A>	AB	PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar	NEWA
>A>	AB		EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar	NEWA
>A>	AB		EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar	NEWA
>A>	AB		EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar	NEWA

METOPROLOL TARTRATE

TABLET;ORAL  
METOPROLOL TARTRATE

	@	HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb	DISC
	@		100MG	A074141	002	Jan 31, 1995	Feb	DISC
AB		YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	NEWA
AB			50MG	A208955	002	Feb 05, 2020	Jan	NEWA
AB			100MG	A208955	003	Feb 05, 2020	Jan	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION  
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

	@	MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan	DISC
	@		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan	DISC

MIDODRINE HYDROCHLORIDE

TABLET;ORAL  
MIDODRINE HYDROCHLORIDE

>D>	@	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
>D>	@		5MG	A076514	002	Sep 11, 2003	Mar	CAHN
>D>	@		10MG	A076514	003	Jul 02, 2004	Mar	CAHN
>A>	@	CHARTWELL RX	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
>A>	@		5MG	A076514	002	Sep 11, 2003	Mar	CAHN
>A>	@		10MG	A076514	003	Jul 02, 2004	Mar	CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION  
MILRINONE LACTATE

>A>	AP	NANJING KING-FRIEND	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Mar	NEWA
-----	----	---------------------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
XIMINO

	JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012	Feb	CAHN
	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Feb	CAHN
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Feb	CAHN
	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Feb	CAHN
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Feb	CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL  
MIRABEGRON

	@	SAWAI USA	25MG	A209446	001	Dec 27, 2019	Jan	DISC
	+	APGDI	25MG	N202611	001	Jun 28, 2012	Jan	CTEC

MOMETASONE FUROATE

SPRAY, METERED;NASAL  
MOMETASONE FUROATE

>D>	AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar	CPOT	
>A>	AB		0.05MG/SPRAY	A207989	001	Apr 03, 2017	Mar	CPOT	
>D>	AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar	CPOT	
>A>	AB		0.05MG/SPRAY	A091161	001	Mar 22, 2016	Mar	CPOT	
		NASONEX							
>D>	AB	+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar	CPOT
>A>	AB	+		0.05MG/SPRAY	N020762	001	Oct 01, 1997	Mar	CPOT

MONTELUKAST SODIUM

GRANULE;ORAL  
MONTELUKAST SODIUM

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE/PACKET	A213471	001	Feb 18, 2020	Feb	NEWA
----	--	----------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

MONTELUKAST SODIUM

@ HIKMA

EQ 10MG BASE

A090655 001 Aug 03, 2012 Feb DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

@ JUBILANT GENERICS

EQ 4MG BASE

A203795 001 Feb 27, 2015 Jan DISC

@

EQ 5MG BASE

A203795 002 Feb 27, 2015 Jan DISC

MORPHINE SULFATEINJECTABLE;INJECTION

DURAMORPH PF

AP +! HIKMA 0.5MG/ML

N018565 001 Sep 18, 1984 Feb CAHN

AP +! 1MG/ML

N018565 002 Sep 18, 1984 Feb CAHN

INFUMORPH

AP +! HIKMA 10MG/ML

N018565 003 Jul 19, 1991 Feb CAHN

AP +! 25MG/ML

N018565 004 Jul 19, 1991 Feb CAHN

MORPHINE SULFATE

AP HIKMA 4MG/ML

A205758 001 May 21, 2015 Feb CAHN

AP 8MG/ML

A205758 002 May 21, 2015 Feb CAHN

AP 10MG/ML

A205758 003 May 21, 2015 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

&gt;D&gt; AB NESHER PHARMS 15MG

A076733 001 May 19, 2004 Mar DISC

&gt;A&gt; @ 15MG

A076733 001 May 19, 2004 Mar DISC

&gt;D&gt; AB 100MG

A077855 001 Sep 27, 2007 Mar DISC

&gt;A&gt; @ 100MG

A077855 001 Sep 27, 2007 Mar DISC

&gt;D&gt; AB 200MG

A077855 002 Sep 27, 2007 Mar DISC

&gt;A&gt; @ 200MG

A077855 002 Sep 27, 2007 Mar DISC

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

&gt;A&gt; AT1 GLAND PHARMA LTD EQ 0.5% BASE

A208778 001 Mar 30, 2020 Mar NEWA

&gt;A&gt; AT1 MYLAN EQ 0.5% BASE

A206447 001 Mar 30, 2020 Mar NEWA

MYCOPHENOLIC ACIDTABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

&gt;D&gt; AB TEVA PHARMS USA 180MG

A202720 001 Oct 30, 2014 Mar DISC

&gt;A&gt; @ 180MG

A202720 001 Oct 30, 2014 Mar DISC

&gt;D&gt; AB 360MG

A202720 002 Oct 30, 2014 Mar DISC

&gt;A&gt; @ 360MG

A202720 002 Oct 30, 2014 Mar DISC

NABILONECAPSULE;ORAL

CESAMET

&gt;A&gt; +! BAUSCH 1MG

N018677 001 Dec 26, 1985 Mar CAHN

&gt;D&gt; +! MYLAN SPECIALITY LP 1MG

N018677 001 Dec 26, 1985 Mar CAHN

NADOLOLTABLET;ORAL

NADOLOL

&gt;D&gt; AB VGYAAN 20MG

A212856 001 Sep 13, 2019 Mar DISC

&gt;A&gt; @ 20MG

A212856 001 Sep 13, 2019 Mar DISC

&gt;D&gt; AB 40MG

A212856 002 Sep 13, 2019 Mar DISC

&gt;A&gt; @ 40MG

A212856 002 Sep 13, 2019 Mar DISC

&gt;D&gt; AB 80MG

A212856 003 Sep 13, 2019 Mar DISC

&gt;A&gt; @ 80MG

A212856 003 Sep 13, 2019 Mar DISC

NALBUPHINE HYDROCHLORIDEINJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

@ MYLAN LABS LTD 10MG/ML

A206506 001 Feb 06, 2019 Feb DISC

@ 10MG/ML

A207595 001 Jan 11, 2019 Feb DISC

@ 20MG/ML

A206506 002 Feb 06, 2019 Feb DISC

@ 20MG/ML

A207595 002 Jan 11, 2019 Feb DISC

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION  
NALOXONE HYDROCHLORIDE

>A>	AP	DR REDDYS	1MG/ML	A213209	001	Mar 16, 2020	Mar NEWA
>D>	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Mar CTEC
>A>	AP	!	1MG/ML	A072076	001	Mar 24, 1988	Mar CTEC
	AP	PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jan NEWA

NAPROXENTABLET; ORAL  
NAPROXEN

	@	MYLAN	250MG	A074121	001	Dec 21, 1993	Jan DISC
	@		375MG	A074121	002	Dec 21, 1993	Jan DISC
	@		500MG	A074121	003	Dec 21, 1993	Jan DISC
AB		SCIEGEN PHARMS INC	250MG	A212517	001	Feb 21, 2020	Feb NEWA
AB			375MG	A212517	002	Feb 21, 2020	Feb NEWA
AB			500MG	A212517	003	Feb 21, 2020	Feb NEWA

TABLET, DELAYED RELEASE; ORAL  
NAPROXEN

>D>	AB	PLIVA	375MG	A075337	001	May 26, 1999	Mar DISC
>A>		@	375MG	A075337	001	May 26, 1999	Mar DISC
>D>	AB		500MG	A075337	002	May 26, 1999	Mar DISC
>A>		@	500MG	A075337	002	May 26, 1999	Mar DISC

NAPROXEN SODIUMTABLET; ORAL  
NAPROXEN SODIUM

>D>	AB	TEVA	EQ 250MG BASE	A074198	001	Dec 21, 1993	Mar DISC
>A>		@	EQ 250MG BASE	A074198	001	Dec 21, 1993	Mar DISC
>D>	AB		EQ 500MG BASE	A074198	002	Dec 21, 1993	Mar DISC
>A>		@	EQ 500MG BASE	A074198	002	Dec 21, 1993	Mar DISC

NARATRIPTAN HYDROCHLORIDETABLET; ORAL  
NARATRIPTAN

>D>		@	CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar CAHN
>D>		@		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar CAHN
>A>		@	CHARTWELL RX	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar CAHN
>A>		@		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar CAHN

NATEGLINIDETABLET; ORAL  
NATEGLINIDE

>D>	AB	ALVOGEN	60MG	A205055	001	Dec 11, 2015	Mar DISC
>A>		@	60MG	A205055	001	Dec 11, 2015	Mar DISC
>D>	AB		120MG	A205055	002	Dec 11, 2015	Mar DISC
>A>		@	120MG	A205055	002	Dec 11, 2015	Mar DISC

NEOMYCIN SULFATETABLET; ORAL  
NEOMYCIN SULFATE

AA		XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb CAHN
----	--	-------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION; IRRIGATION  
NEOMYCIN AND POLYMYXIN B SULFATE

>D>		@	WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Mar CMFD
>A>	AT			EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Mar CMFD
	AT		XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb CAHN
	AT			EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb CAHN

NETARSUDIL MESYLATESOLUTION/DROPS; OPHTHALMIC  
RHOPRESSA

+!		AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb CAIN
----	--	------------------	---------------	---------	-----	--------------	----------

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

@	MYLAN	500MG	A203742	001	Feb 22, 2019	Jan	DISC
@		750MG	A203742	002	Feb 22, 2019	Jan	DISC
@		1GM	A203742	003	Feb 22, 2019	Jan	DISC

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan	CAHN
---	-----------------	---------------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

>D>	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
>A>	BX	+	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
>D>	+		0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
>A>	BX	+	0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
>D>	+		0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
>A>	BX	+	0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
>D>	+		0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC
>A>	BX	+	0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC

TABLET;SUBLINGUAL

NITROGLYCERIN

>D>	AB	ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Mar	DISC
>A>		@	0.3MG	A203693	001	Oct 16, 2017	Mar	DISC
>D>	AB		0.4MG	A203693	002	Oct 16, 2017	Mar	DISC
>A>		@	0.4MG	A203693	002	Oct 16, 2017	Mar	DISC
>D>	AB		0.6MG	A203693	003	Oct 16, 2017	Mar	DISC
>A>		@	0.6MG	A203693	003	Oct 16, 2017	Mar	DISC

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+	TEVA BRANDED PHARM	0.35MG	N017060	001		Jan	CAHN
-----	---	--------------------	--------	---------	-----	--	-----	------

NYSTATIN

POWDER;TOPICAL

NYSTATIN

AT		XGEN PHARMS	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Feb	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D>		@	ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	CMFD
>A>	AT			100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	CMFD

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

@	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Feb	DISC
@		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Feb	DISC
@		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Feb	DISC

SOLUTION;SUBCUTANEOUS

BYNFEZIA PEN

+	SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N213224	001	Jan 28, 2020	Jan	NEWA
---	-----------	-------------------------------------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>D>	AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Mar	DISC	
>A>		@	20MG	A077301	001	Apr 29, 2015	Mar	DISC	
		@	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC
		@		5MG	A076000	002	Oct 24, 2011	Jan	DISC
		@		7.5MG	A076000	003	Oct 24, 2011	Jan	DISC
		@		10MG	A076000	004	Oct 24, 2011	Jan	DISC
		@		15MG	A076000	005	Oct 24, 2011	Jan	DISC

OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL

	@	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC
	@		20MG	A205482	002	Apr 24, 2017	Feb	DISC
	@		40MG	A205482	003	Apr 24, 2017	Feb	DISC
>A>	AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar	NEWA
>A>	AB		20MG	A090237	002	Apr 13, 2020	Mar	NEWA
>A>	AB		40MG	A090237	003	Apr 13, 2020	Mar	NEWA

OLOPATADINE HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## OLOPATADINE HYDROCHLORIDE

>D>	AT	CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC
>A>		@	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC
>D>	AT		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC
>A>		@	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC
>D>	AT	WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC
>A>		@	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC
	AT		EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb	NFTG
>D>	AT	NOVARTIS	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar	CMS1
>D>		PATANOL						
>D>	AT	NOVARTIS	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar	CMS1
		PAZEO						
>D>	AT	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar	CTEC
>A>		NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar	CTEC
	AT	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb	CFTG
		SPRAY, METERED; NASAL						
		OLOPATADINE HYDROCHLORIDE						
AB		AMNEAL PHARMS LLC	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	NEWA

OMEGA-3-ACID ETHYL ESTERS

## CAPSULE; ORAL

## OMEGA-3-ACID ETHYL ESTERS

AB		SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb	CMFD
----	--	---------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE

## CAPSULE, DELAYED REL PELLETS; ORAL

## OMEPRAZOLE

	@	MYLAN	10MG	A205070	001	Jun 29, 2018	Feb	DISC
	@		20MG	A075876	002	May 29, 2003	Jan	DISC
	@		20MG	A205070	002	Jun 29, 2018	Feb	DISC
	@		40MG	A205070	003	Jun 29, 2018	Feb	DISC

ONDANSETRON

## TABLET, ORALLY DISINTEGRATING; ORAL

## ONDANSETRON

>D>	AB	BARR	4MG	A076693	001	Jun 25, 2007	Mar	DISC
>A>		@	4MG	A076693	001	Jun 25, 2007	Mar	DISC
>D>	AB		8MG	A076693	002	Jun 25, 2007	Mar	DISC
>A>		@	8MG	A076693	002	Jun 25, 2007	Mar	DISC
>D>	AB	TEVA	4MG	A076810	001	Jun 25, 2007	Mar	DISC
>A>		@	4MG	A076810	001	Jun 25, 2007	Mar	DISC
>D>	AB		8MG	A076810	002	Jun 25, 2007	Mar	DISC
>A>		@	8MG	A076810	002	Jun 25, 2007	Mar	DISC

ONDANSETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## ONDANSETRON HYDROCHLORIDE

>D>	AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Mar	DISC
>A>		@		EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Mar	DISC
>D>	AP		QILU	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Mar	CHRS
>A>	AP	!		EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Mar	CHRS

## TABLET; ORAL

## ONDANSETRON HYDROCHLORIDE

		@	MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan	DISC
		@		EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan	DISC
>D>	AB		PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112	001	Jun 25, 2007	Mar	DISC



## TABLET;ORAL

## ONDANSETRON HYDROCHLORIDE

>A>	@	EQ 4MG BASE	A077112	001	Jun 25, 2007	Mar	DISC
>D>	AB	EQ 8MG BASE	A077112	002	Jun 25, 2007	Mar	DISC
>A>	@	EQ 8MG BASE	A077112	002	Jun 25, 2007	Mar	DISC
>D>	AB	EQ 24MG BASE	A077112	003	Jun 25, 2007	Mar	DISC
>A>	@	EQ 24MG BASE	A077112	003	Jun 25, 2007	Mar	DISC

OSELTAMIVIR PHOSPHATE

## CAPSULE;ORAL

## OSELTAMIVIR PHOSPHATE

AB	SUNSHINE LAKE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Feb	NEWA
AB		EQ 45MG BASE	A212739	002	Mar 04, 2020	Feb	NEWA
AB		EQ 75MG BASE	A212739	003	Mar 04, 2020	Feb	NEWA

>A>	<u>OSILODROSTAT PHOSPHATE</u>							
>A>	TABLET;ORAL							
>A>	ISTURISA							
>A>	+	RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020	Mar	NEWA
>A>	+		EQ 5MG BASE	N212801	002	Mar 06, 2020	Mar	NEWA
>A>	+	!	EQ 10MG BASE	N212801	003	Mar 06, 2020	Mar	NEWA

OXAPROZIN

## TABLET;ORAL

## OXAPROZIN

>D>	AB	APOTEX INC	600MG	A075987	001	Sep 02, 2004	Mar	CAHN
>A>	AB	CHARTWELL	600MG	A075987	001	Sep 02, 2004	Mar	CAHN
>D>	AB	IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002	Mar	DISC
>A>	@		600MG	A075846	001	May 13, 2002	Mar	DISC

OXAZEPAM

## CAPSULE;ORAL

## OXAZEPAM

>D>	@	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Mar	CMFD
>A>	AB		10MG	A071026	002	Aug 10, 1987	Mar	CMFD
>D>	@		15MG	A071026	003	Aug 10, 1987	Mar	CMFD
>A>	AB		15MG	A071026	003	Aug 10, 1987	Mar	CMFD
>D>	@		30MG	A071026	001	Aug 10, 1987	Mar	CMFD
>A>	AB		30MG	A071026	001	Aug 10, 1987	Mar	CMFD

OXCARBAZEPINE

## TABLET;ORAL

## OXCARBAZEPINE

@	HIKMA	150MG	A077795	001	Oct 09, 2007	Feb	DISC
@		300MG	A077795	002	Oct 09, 2007	Feb	DISC
@		600MG	A077795	003	Oct 09, 2007	Feb	DISC

OXYBUTYNIN CHLORIDE

## TABLET;ORAL

## OXYBUTYNIN CHLORIDE

>A>	AB	LEADING PHARMA LLC	5MG	A212798	001	Apr 06, 2020	Mar	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		OXYBUTYNIN CHLORIDE						
	@	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan	DISC
	@		15MG	A076644	002	May 10, 2007	Jan	DISC

OXYCODONE HYDROCHLORIDE

## SOLUTION;ORAL

## OXYCODONE HYDROCHLORIDE

@	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan	DISC
AA	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan	NEWA
AA		100MG/5ML	A212429	002	Jan 27, 2020	Jan	NEWA
@	HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb	DISC

## TABLET;ORAL

## OXYCODONE HYDROCHLORIDE

>D>	AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar	DISC
>A>	@		5MG	A077290	001	Dec 08, 2005	Mar	DISC
>D>	AB		10MG	A077290	002	Dec 08, 2005	Mar	DISC
>A>	@		10MG	A077290	002	Dec 08, 2005	Mar	DISC
>D>	AB		15MG	A077290	003	Dec 08, 2005	Mar	DISC
>A>	@		15MG	A077290	003	Dec 08, 2005	Mar	DISC
>D>	AB		20MG	A077290	004	Dec 08, 2005	Mar	DISC

## TABLET;ORAL

## OXYCODONE HYDROCHLORIDE

>A>	@	20MG	A077290	004	Dec 08, 2005	Mar	DISC
>D>	AB	30MG	A077290	005	Dec 08, 2005	Mar	DISC
>A>	@	30MG	A077290	005	Dec 08, 2005	Mar	DISC

OXYMORPHONE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## OXYMORPHONE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar	DISC
>A>	@		5MG	A079046	003	Jul 11, 2013	Mar	DISC
>D>	AB		7.5MG	A079046	001	Dec 13, 2010	Mar	DISC
>A>	@		7.5MG	A079046	001	Dec 13, 2010	Mar	DISC
>D>	AB		10MG	A079046	004	Jul 11, 2013	Mar	DISC
>A>	@		10MG	A079046	004	Jul 11, 2013	Mar	DISC
>D>	AB		15MG	A079046	002	Dec 13, 2010	Mar	DISC
>A>	@		15MG	A079046	002	Dec 13, 2010	Mar	DISC
>D>	AB		20MG	A079046	005	Jul 11, 2013	Mar	DISC
>A>	@		20MG	A079046	005	Jul 11, 2013	Mar	DISC
>D>	AB		30MG	A079046	006	Jul 11, 2013	Mar	DISC
>A>	@		30MG	A079046	006	Jul 11, 2013	Mar	DISC
>D>	AB		40MG	A079046	007	Jul 11, 2013	Mar	DISC
>A>	@		40MG	A079046	007	Jul 11, 2013	Mar	DISC

OZANIMOD HYDROCHLORIDE

## CAPSULE;ORAL

## ZEPOSIA

>A>	+	CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar	NEWA
>A>	+		0.46MG	N209899	002	Mar 25, 2020	Mar	NEWA
>A>	+	!	0.92MG	N209899	003	Mar 25, 2020	Mar	NEWA

PAMIDRONATE DISODIUM

## INJECTABLE;INJECTION

## PAMIDRONATE DISODIUM

>D>	AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar	DISC
>A>	@		30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar	DISC
>D>	AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar	DISC
>A>	@		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar	DISC

PAROXETINE HYDROCHLORIDE

## TABLET;ORAL

## PAROXETINE HYDROCHLORIDE

@	JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan	DISC
@		EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan	DISC
@		EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan	DISC
@		EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan	DISC

PASIREOTIDE DIASPARTATE

## SOLUTION;SUBCUTANEOUS

## SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb	CAHN
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb	CAHN
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb	CAHN

PASIREOTIDE PAMOATE

## FOR SUSPENSION;INTRAMUSCULAR

## SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb	CAHN
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb	CAHN
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb	CAHN
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb	CAHN
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb	CAHN

PAZOPANIB HYDROCHLORIDE

## TABLET;ORAL

## VOTRIENT

+	@	NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan	CRLD
---	---	----------	---------------	---------	-----	--------------	-----	------

PEMETREXEDSOLUTION; INTRAVENOUS  
PEMFEXY

+! EAGLE PHARMS 500MG/20ML (25MG/ML) N209472 001 Feb 08, 2020 Feb NEWA

PENICILLAMINECAPSULE; ORAL  
PENICILLAMINE

AB ANI PHARMS INC 250MG A209921 001 May 07, 2019 Jan CAHN

TABLET; ORAL  
PENICILLAMINE

AB TEVA PHARMS USA 250MG A211497 001 Feb 13, 2020 Feb NEWA

PERMETHRINCREAM; TOPICAL  
ELIMITE

+ @ MYLAN 5% N019855 001 Aug 25, 1989 Feb DISC

PERMETHRIN

AB ! PERRIGO ISRAEL 5% A076369 001 Apr 21, 2003 Feb CHRS

PERPHENAZINETABLET; ORAL  
PERPHENAZINE

&gt;A&gt; AB ZYDUS PHARMS 2MG A205232 001 Apr 06, 2020 Mar NEWA

&gt;A&gt; AB 4MG A205232 002 Apr 06, 2020 Mar NEWA

&gt;A&gt; AB 8MG A205232 003 Apr 06, 2020 Mar NEWA

&gt;A&gt; AB 16MG A205232 004 Apr 06, 2020 Mar NEWA

PHENDIMETRAZINE TARTRATETABLET; ORAL  
PHENDIMETRAZINE TARTRATE

&gt;D&gt; AA ELITE LABS INC 35MG A203600 001 Dec 27, 2017 Mar CAHN

&gt;A&gt; AA NOSTRUM LABS INC 35MG A203600 001 Dec 27, 2017 Mar CAHN

&gt;A&gt; AA 35MG A203600 001 Dec 27, 2017 Mar CAHN

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL  
PHENTERMINE HYDROCHLORIDE

&gt;D&gt; AA BARR 15MG A090591 001 Mar 18, 2010 Mar DISC

&gt;A&gt; @ 15MG A090591 001 Mar 18, 2010 Mar DISC

&gt;D&gt; AA 30MG A090591 002 Mar 18, 2010 Mar DISC

&gt;A&gt; @ 30MG A090591 002 Mar 18, 2010 Mar DISC

TABLET; ORAL  
PHENTERMINE HYDROCHLORIDE

&gt;D&gt; AA BARR 37.5MG A090470 001 Aug 31, 2009 Mar DISC

&gt;A&gt; @ 37.5MG A090470 001 Aug 31, 2009 Mar DISC

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

AP1 RICONPHARMA LLC 10MG/ML (10MG/ML) A209967 001 Jan 16, 2020 Jan NEWA

AP1 50MG/5ML (10MG/ML) A209967 002 Jan 16, 2020 Jan NEWA

AP1 100MG/10ML (10MG/ML) A209967 003 Jan 16, 2020 Jan NEWA

PILOCARPINE HYDROCHLORIDETABLET; ORAL  
PILOCARPINE HYDROCHLORIDE

&gt;D&gt; @ AUROBINDO PHARMA LTD 5MG A212377 001 Aug 13, 2019 Mar CMFD

&gt;A&gt; AB 5MG A212377 001 Aug 13, 2019 Mar CMFD

&gt;D&gt; @ 5MG A212377 001 Aug 13, 2019 Feb DISC

&gt;D&gt; @ 7.5MG A212377 002 Aug 13, 2019 Mar CMFD

&gt;A&gt; AB 7.5MG A212377 002 Aug 13, 2019 Mar CMFD

&gt;A&gt; @ 7.5MG A212377 002 Aug 13, 2019 Feb DISC

PIOGLITAZONE HYDROCHLORIDETABLET; ORAL  
PIOGLITAZONE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 15MG BASE A076801 001 Aug 17, 2012 Jan DISC

@ EQ 30MG BASE A076801 002 Aug 17, 2012 Jan DISC

@ EQ 45MG BASE A076801 003 Aug 17, 2012 Jan DISC

PIROXICAMCAPSULE;ORAL  
PIROXICAM

>D>	AB	PII	10MG	A206136	001	Jun 20, 2017	Mar	CAHN
>D>	AB		20MG	A206136	002	Jun 20, 2017	Mar	CAHN
>A>	AB	STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Mar	CAHN
>A>	AB		20MG	A206136	002	Jun 20, 2017	Mar	CAHN

PODOFILOXSOLUTION;TOPICAL  
CONDYLOX

AT	+	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan	CAHN
----	---	--------------------	------	---------	-----	--------------	-----	------

POLYMYXIN B SULFATEINJECTABLE;INJECTION  
AEROSPORIN

		@ GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036	001		Jan	CMS1
AP		POLYMYXIN B SULFATE XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

>D>	AB	PII	8MEQ	A205549	001	Dec 08, 2015	Mar	CAHN
>D>	AB		10MEQ	A205549	002	Dec 08, 2015	Mar	CAHN
>A>	AB	STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015	Mar	CAHN
>A>	AB		10MEQ	A205549	002	Dec 08, 2015	Mar	CAHN

FOR SUSPENSION, EXTENDED RELEASE;ORAL  
MICRO-K LS

+ @ KV PHARM 20MEQ/PACKET

N019561	003	Aug 26, 1988	Feb	CRLD
---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB2		GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb	NEWA
AB2			10MEQ	A211797	002	Mar 04, 2020	Feb	NEWA
		@ STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019	Feb	CAHN
		@	10MEQ	A206881	002	Jan 22, 2019	Feb	CAHN
		@	10MEQ	A210097	001	Jun 17, 2019	Feb	CAHN
		@	20MEQ	A210098	001	Apr 26, 2019	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

		@ MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan	DISC
		@	0.25MG	A077854	002	Oct 08, 2010	Jan	DISC
		@	0.5MG	A077854	003	Oct 08, 2010	Jan	DISC
		@	0.75MG	A090764	001	Apr 09, 2010	Jan	DISC
		@	1MG	A077854	004	Oct 08, 2010	Jan	DISC
		@	1.5MG	A077854	005	Oct 08, 2010	Jan	DISC
AB		ZENNOVA	0.125MG	A090151	001	Apr 30, 2012	Feb	CAHN
AB			0.25MG	A090151	002	Apr 30, 2012	Feb	CAHN
AB			0.5MG	A090151	003	Apr 30, 2012	Feb	CAHN
AB			0.75MG	A090151	006	Apr 30, 2012	Feb	CAHN
AB			1MG	A090151	004	Apr 30, 2012	Feb	CAHN
AB			1.5MG	A090151	005	Apr 30, 2012	Feb	CAHN

PREDNICARBATEOINTMENT;TOPICAL  
DERMATOP

		+ @ VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Feb	DISC
		PREDNICARBATE						
		! FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Feb	CTEC
AB		!	0.1%	A077236	001	Mar 09, 2007	Feb	CHRS

PREDNISOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC  
OMNIPRED

AB	+	NOVARTIS	1%	N017469	001		Jan	CHRS
AB	+		1%	N017469	001		Jan	CRLD

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

PHARM ASSOC

EQ 30MG BASE/5ML

A204962 001 Mar 11, 2020 Feb NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

>A>	AB	CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar	NEWA
>A>	AB		75MG	A212865	002	Mar 20, 2020	Mar	NEWA
>A>	AB		100MG	A212865	003	Mar 20, 2020	Mar	NEWA
>A>	AB		150MG	A212865	004	Mar 20, 2020	Mar	NEWA
>A>	AB	HIKAL	25MG	A213423	001	Mar 23, 2020	Mar	NEWA
>A>	AB		50MG	A213423	002	Mar 23, 2020	Mar	NEWA
>A>	AB		75MG	A213423	003	Mar 23, 2020	Mar	NEWA
>A>	AB		100MG	A213423	004	Mar 23, 2020	Mar	NEWA
>A>	AB		150MG	A213423	005	Mar 23, 2020	Mar	NEWA
>A>	AB		200MG	A213423	006	Mar 23, 2020	Mar	NEWA
>A>	AB		225MG	A213423	007	Mar 23, 2020	Mar	NEWA
>A>	AB		300MG	A213423	008	Mar 23, 2020	Mar	NEWA
		@ MYLAN	25MG	A091228	001	Sep 20, 2019	Feb	DISC
		@	50MG	A091228	002	Sep 20, 2019	Feb	DISC
		@	75MG	A091228	003	Sep 20, 2019	Feb	DISC
		@	100MG	A091228	004	Sep 20, 2019	Feb	DISC
		@	150MG	A091228	005	Sep 20, 2019	Feb	DISC
		@	200MG	A091228	006	Sep 20, 2019	Feb	DISC
		@	225MG	A091228	007	Sep 20, 2019	Feb	DISC
		@	300MG	A091228	008	Sep 20, 2019	Feb	DISC

PROCHLORPERAZINE MALEATE

TABLET;ORAL

COMPAZINE

>D>		@ GLAXOSMITHKLINE	EQ 5MG BASE	N010571	001		Mar	CRLD
>A>	+	@	EQ 5MG BASE	N010571	001		Mar	CRLD
>D>		@	EQ 10MG BASE	N010571	002		Mar	CRLD
>A>	+	@	EQ 10MG BASE	N010571	002		Mar	CRLD
>D>		@	EQ 25MG BASE	N010571	003		Mar	CRLD
>A>	+	@	EQ 25MG BASE	N010571	003		Mar	CRLD
			PROCHLORPERAZINE MALEATE					
>D>	AB	SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996	Mar	DISC
>A>		@	EQ 5MG BASE	A040101	001	Jul 19, 1996	Mar	DISC
>D>	AB	!	EQ 10MG BASE	A040101	002	Jul 19, 1996	Mar	DISC
>A>		@	EQ 10MG BASE	A040101	002	Jul 19, 1996	Mar	DISC
			PROCOMP					
>D>	AB	JUBILANT CADISTA	EQ 10MG BASE	A040268	002	Feb 27, 1998	Mar	CHRS
>A>	AB	!	EQ 10MG BASE	A040268	002	Feb 27, 1998	Mar	CHRS

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP XGEN PHARMS

25MG/ML

A040737 001 Apr 24, 2008 Feb CAHN

AP

50MG/ML

A040737 002 Apr 24, 2008 Feb CAHN

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

>D>	AB	WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003	Mar	DISC
>A>		@	12.5MG	A040479	001	Jun 24, 2003	Mar	DISC
>D>	AB		25MG	A040479	002	Jun 24, 2003	Mar	DISC
>A>		@	25MG	A040479	002	Jun 24, 2003	Mar	DISC

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

! AKORN

500MG

A081319 001 Jun 30, 1992 Feb CHRS

500MG

A081319 001 Jun 30, 1992 Feb CTEC

@ DAVA PHARMS INC

500MG

A080157 001 Feb DISC

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

AB	+!	VYERA PHARMS LLC	25MG	N008578	001		Feb	CFTG
AB		CEROVENE INC	25MG	A207127	001	Feb 28, 2020	Feb	NFTG

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ZENNOVA	EQ 25MG BASE	A090960	001	Mar 27, 2012	Feb	CAHN
AB			EQ 50MG BASE	A090960	002	Mar 27, 2012	Feb	CAHN
AB			EQ 100MG BASE	A090960	003	Mar 27, 2012	Feb	CAHN
AB			EQ 200MG BASE	A090960	004	Mar 27, 2012	Feb	CAHN
AB			EQ 300MG BASE	A090960	005	Mar 27, 2012	Feb	CAHN
AB			EQ 400MG BASE	A090960	006	Mar 27, 2012	Feb	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>D>	AB	MYLAN	EQ 5MG BASE	A076694	001	Dec 23, 2004	Mar	DISC
>A>		@	EQ 5MG BASE	A076694	001	Dec 23, 2004	Mar	DISC
>D>	AB		EQ 10MG BASE	A076694	002	Dec 23, 2004	Mar	DISC
>A>		@	EQ 10MG BASE	A076694	002	Dec 23, 2004	Mar	DISC
>D>	AB		EQ 20MG BASE	A076694	003	Dec 23, 2004	Mar	DISC
>A>		@	EQ 20MG BASE	A076694	003	Dec 23, 2004	Mar	DISC
>D>	AB		EQ 40MG BASE	A076694	004	Dec 23, 2004	Mar	DISC
>A>		@	EQ 40MG BASE	A076694	004	Dec 23, 2004	Mar	DISC

RAMELTEON

TABLET; ORAL

RAMELTEON

>A>	AB	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar	NEWA
-----	----	-----------	-----	---------	-----	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

>D>	AB	TEVA PHARMS	1.25MG	A077470	001	Jun 18, 2008	Mar	DISC
>A>		@	1.25MG	A077470	001	Jun 18, 2008	Mar	DISC
>D>	AB		2.5MG	A077470	002	Jun 18, 2008	Mar	DISC
>A>		@	2.5MG	A077470	002	Jun 18, 2008	Mar	DISC
>D>	AB		5MG	A077470	003	Jun 18, 2008	Mar	DISC
>A>		@	5MG	A077470	003	Jun 18, 2008	Mar	DISC
>D>	AB		10MG	A077470	004	Jun 18, 2008	Mar	DISC
>A>		@	10MG	A077470	004	Jun 18, 2008	Mar	DISC

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ AMNEAL PHARMS NY EQ 150MG BASE

@ EQ 300MG BASE

@ STRIDES PHARMA EQ 150MG BASE

@ EQ 300MG BASE

A077824	001	Oct 13, 2006	Jan	DISC
A077824	002	Oct 13, 2006	Jan	DISC
A210010	001	Aug 01, 2018	Jan	DISC
A210010	002	Aug 01, 2018	Jan	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANOLAZINE

AB		ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan	CAHN
AB			1GM	A210482	002	Oct 29, 2019	Jan	CAHN
AB		MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan	NEWA
AB			1GM	A212284	002	Feb 12, 2020	Jan	NEWA
AB		MICRO LABS	500MG	A211745	001	Feb 27, 2020	Feb	NEWA
AB			1GM	A211745	002	Feb 27, 2020	Feb	NEWA
>A>	AB	SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Mar	NEWA
>A>	AB		1GM	A212781	002	Mar 23, 2020	Mar	NEWA
>A>	AB	SUNSHINE LAKE	500MG	A211865	001	Mar 23, 2020	Mar	NEWA
>A>	AB		1GM	A211865	002	Mar 23, 2020	Mar	NEWA

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

>D>	AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Mar	DISC
>A>		@	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Mar	DISC
>D>	AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Mar	DISC
>A>		@	EQ 1MG BASE	A201823	002	Jul 01, 2013	Mar	DISC

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

>D>	AB	ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Mar	DISC
>A>		@	0.5MG	A090008	001	Jan 22, 2014	Mar	DISC
>D>	AB		1MG	A090008	002	Jan 22, 2014	Mar	DISC
>A>		@	1MG	A090008	002	Jan 22, 2014	Mar	DISC
>D>	AB		2MG	A090008	003	Jan 22, 2014	Mar	DISC
>A>		@	2MG	A090008	003	Jan 22, 2014	Mar	DISC

RIBAVIRIN

CAPSULE; ORAL

RIBASPHERE

		@ KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Feb	DISC
		RIBAVIRIN						
>D>		@ CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Mar	CAHN
>A>		@ CHARTWELL RX	200MG	A076192	001	Apr 06, 2004	Mar	CAHN
>D>	AB	TEVA	200MG	A076277	001	Oct 04, 2004	Mar	DISC
>A>		@	200MG	A076277	001	Oct 04, 2004	Mar	DISC

TABLET; ORAL

RIBAVIRIN

		@ BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb	DISC
		@	400MG	A202546	002	Aug 12, 2014	Feb	DISC
		@	500MG	A202546	003	Aug 12, 2014	Feb	DISC
		@	600MG	A202546	004	Aug 12, 2014	Feb	DISC
		@ KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Feb	DISC
		@	400MG	A077456	002	Dec 05, 2005	Feb	DISC
		@	600MG	A077456	003	Dec 05, 2005	Feb	DISC
		@ ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007	Feb	DISC
		@	500MG	A077094	004	Apr 18, 2008	Feb	DISC
		@	600MG	A077094	003	Mar 16, 2007	Feb	DISC

RILUZOLE

TABLET; ORAL

RILUZOLE

>A>	AB	KENTON	50MG	A206045	001	Dec 09, 2019	Mar	CAHN
>D>	AB	STANDARD CHEM PHARM	50MG	A206045	001	Dec 09, 2019	Mar	CAHN

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING; ORAL

NURTEC ODT

+	!	BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb	NEWA
---	---	----------------	--------------	---------	-----	--------------	-----	------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

>D>	AB	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011	Mar	DISC
>A>		@	0.5MG	A076996	001	Apr 19, 2011	Mar	DISC
>D>	AB		1MG	A076996	002	Apr 19, 2011	Mar	DISC
>A>		@	1MG	A076996	002	Apr 19, 2011	Mar	DISC
>D>	AB		2MG	A076996	003	Apr 19, 2011	Mar	DISC
>A>		@	2MG	A076996	003	Apr 19, 2011	Mar	DISC
>D>	AB		3MG	A076996	004	Apr 19, 2011	Mar	DISC
>A>		@	3MG	A076996	004	Apr 19, 2011	Mar	DISC
>D>	AB		4MG	A076996	005	Apr 19, 2011	Mar	DISC
>A>		@	4MG	A076996	005	Apr 19, 2011	Mar	DISC

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

YUTOPAR

		@ ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan	CMS1
--	--	---------------	---------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL  
RIZATRIPTAN BENZOATE

@ MYLAN PHARMS INC EQ 5MG BASE A078173 001 Dec 31, 2012 Feb DISC  
@ EQ 10MG BASE A078173 002 Dec 31, 2012 Feb DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION  
ROCURONIUM BROMIDE

>D> AP TEVA PHARMS 50MG/5ML (10MG/ML) A078717 001 Nov 26, 2008 Mar DISC  
>A> @ 50MG/5ML (10MG/ML) A078717 001 Nov 26, 2008 Mar DISC  
>D> AP 100MG/10ML (10MG/ML) A078717 002 Nov 26, 2008 Mar DISC  
>A> @ 100MG/10ML (10MG/ML) A078717 002 Nov 26, 2008 Mar DISC

ROFLUMILAST

TABLET;ORAL  
ROFLUMILAST

>A> AB STRIDES PHARMA 500MCG A208247 001 Mar 30, 2020 Mar NEWA

ROMIDEPSIN

>A> SOLUTION;INTRAVENOUS  
>A> ROMIDEPSIN

>A> + TEVA PHARMS USA INC 10MG/2ML (5MG/ML) N208574 001 Mar 13, 2020 Mar NEWA  
>A> +! 27.5MG/5.5ML (5MG/ML) N208574 002 Mar 13, 2020 Mar NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL  
ROPINIROLE HYDROCHLORIDE

@ HIKMA EQ 0.25MG BASE A077852 001 May 05, 2008 Feb DISC  
@ EQ 0.5MG BASE A077852 002 May 05, 2008 Feb DISC  
@ EQ 1MG BASE A077852 003 May 05, 2008 Feb DISC  
@ EQ 2MG BASE A077852 004 May 05, 2008 Feb DISC  
@ EQ 3MG BASE A077852 005 May 05, 2008 Feb DISC  
@ EQ 4MG BASE A077852 006 May 05, 2008 Feb DISC  
@ EQ 5MG BASE A077852 007 May 19, 2008 Feb DISC

TABLET, EXTENDED RELEASE;ORAL  
REQUIP XL

>D> AB + GLAXOSMITHKLINE LLC EQ 8MG BASE N022008 004 Jun 13, 2008 Mar DISC  
>A> + @ EQ 8MG BASE N022008 004 Jun 13, 2008 Mar DISC

ROPINIROLE HYDROCHLORIDE

>D> AB WATSON LABS INC EQ 2MG BASE A200431 001 Jun 06, 2012 Mar DISC  
>A> @ EQ 2MG BASE A200431 001 Jun 06, 2012 Mar DISC  
>D> AB EQ 4MG BASE A200431 002 Jun 06, 2012 Mar DISC  
>A> @ EQ 4MG BASE A200431 002 Jun 06, 2012 Mar DISC  
>D> AB EQ 6MG BASE A200431 003 Jun 06, 2012 Mar DISC  
>A> @ EQ 6MG BASE A200431 003 Jun 06, 2012 Mar DISC  
>D> AB EQ 8MG BASE A200431 004 Jun 06, 2012 Mar DISC  
>A> @ EQ 8MG BASE A200431 004 Jun 06, 2012 Mar DISC  
>D> AB EQ 12MG BASE A200431 005 Jun 06, 2012 Mar DISC  
>A> @ EQ 12MG BASE A200431 005 Jun 06, 2012 Mar DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION  
ROPIVACAINE HYDROCHLORIDE

>A> AP CAPLIN 40MG/20ML (2MG/ML) A212808 001 Apr 09, 2020 Mar NEWA  
>A> AP 100MG/20ML (5MG/ML) A212808 002 Apr 09, 2020 Mar NEWA  
>A> AP 150MG/30ML (5MG/ML) A212808 003 Apr 09, 2020 Mar NEWA  
>A> AP 200MG/20ML (10MG/ML) A212808 004 Apr 09, 2020 Mar NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL  
ROSUVASTATIN CALCIUM

>A> AB SUNSHINE LAKE 5MG A210667 001 Apr 01, 2020 Mar NEWA  
>A> AB 10MG A210667 002 Apr 01, 2020 Mar NEWA  
>A> AB 20MG A210667 003 Apr 01, 2020 Mar NEWA  
>A> AB 40MG A210667 004 Apr 01, 2020 Mar NEWA



SELEGILINE HYDROCHLORIDE

	CAPSULE;ORAL								
	SELEGILINE HYDROCHLORIDE								
	@ DAVA PHARMS INC	5MG			A075352	001	Nov 30, 1998	Feb	DISC
	TABLET;ORAL								
	SELEGILINE HYDROCHLORIDE								
>D>	@ ALLIED	5MG			A074672	001	Apr 01, 1997	Mar	CAHN
>A>	@ MLV	5MG			A074672	001	Apr 01, 1997	Mar	CAHN

SELEXIPAG

TABLET;ORAL  
UPTRAVI

+!	ACTELION PHARMS LTD	0.4MG			N207947	002	Dec 21, 2015	Jan	CHRS
+		1.6MG			N207947	008	Dec 21, 2015	Jan	CHRS

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS  
OZEMPIC

+!	NOVO	4MG/3ML (1.34MG/ML)			N209637	002	Apr 09, 2019	Jan	NEWA
----	------	---------------------	--	--	---------	-----	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	APOTEX INC	EQ 25MG BASE		A076882	001	Feb 06, 2007	Mar	CAHN
>D>	AB		EQ 50MG BASE		A076882	002	Feb 06, 2007	Mar	CAHN
>D>	AB		EQ 100MG BASE		A076882	003	Feb 06, 2007	Mar	CAHN
>A>	AB	VIWIT PHARM	EQ 25MG BASE		A076882	001	Feb 06, 2007	Mar	CAHN
>A>	AB		EQ 25MG BASE		A076882	001	Feb 06, 2007	Mar	CAHN
>A>	AB		EQ 50MG BASE		A076882	002	Feb 06, 2007	Mar	CAHN
>A>	AB		EQ 50MG BASE		A076882	002	Feb 06, 2007	Mar	CAHN
>A>	AB		EQ 100MG BASE		A076882	003	Feb 06, 2007	Mar	CAHN
>A>	AB		EQ 100MG BASE		A076882	003	Feb 06, 2007	Mar	CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

>A>	AB	ANXIN	800MG		A212970	001	Apr 09, 2020	Mar	NEWA
-----	----	-------	-------	--	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB		APPCO	25MG		A207178	001	Mar 02, 2020	Feb	NEWA
AB			50MG		A207178	002	Mar 02, 2020	Feb	NEWA
AB			100MG		A207178	003	Mar 02, 2020	Feb	NEWA

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB		HETERO LABS LTD V	4MG		A204793	001	Feb 14, 2020	Feb	NEWA
AB			8MG		A204793	002	Feb 14, 2020	Feb	NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA		CURIUM	100uCi		A071909	001	Feb 28, 1989	Feb	CAHN
AA			200uCi		A071910	001	Feb 28, 1989	Feb	CAHN

SODIUM IODIDE I-131

SOLUTION;ORAL

HICON

AA	+!	JUBILANT DRAXIMAGE	250-1000mCi		N021305	007	Dec 05, 2011	Jan	CFTG
		SODIUM IODIDE I 131							
AA		INTL ISOTOPES	250-1000mCi		A209166	001	Feb 05, 2020	Jan	NFTG

SODIUM PHENYL BUTYRATE

TABLET;ORAL

SODIUM PHENYL BUTYRATE

	@	ALVOGEN	500MG		A090910	001	Nov 18, 2011	Jan	DISC
--	---	---------	-------	--	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION;ORAL, RECTAL  
SODIUM POLYSTYRENE SULFONATE  
@ HIKMA

15GM/60ML

A089049 001 Nov 17, 1986 Feb DISC

SOFOSBUVIR; VELPATASVIR

TABLET;ORAL  
EPCLUSA

&gt;A&gt; + GILEAD SCIENCES INC 200MG;50MG

N208341 002 Mar 19, 2020 Mar NEWA

SOLIFENACIN SUCCINATE

TABLET;ORAL  
SOLIFENACIN SUCCINATE

&gt;A&gt; AB SUNSHINE LAKE 5MG

A213346 001 Apr 13, 2020 Mar NEWA

&gt;A&gt; AB 10MG

A213346 002 Apr 13, 2020 Mar NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL  
SUNOSI

+ JAZZ EQ 75MG BASE  
+ 75MG

N211230 001 Jun 17, 2019 Jan CPOT

N211230 001 Jun 17, 2019 Jan CAIN

SPIRONOLACTONE

TABLET;ORAL  
SPIRONOLACTONE

&gt;D&gt; @ CASI PHARMS INC 25MG

A086809 001 Mar CAHN

&gt;A&gt; @ CHARTWELL RX 25MG

A086809 001 Mar CAHN

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION  
STREPTOMYCIN SULFATE

! XGEN PHARMS EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998 Feb CAHN

SULFACETAMIDE SODIUM

LOTION;TOPICAL  
KLARON

&gt;A&gt; AB +! BAUSCH 10%

N019931 001 Dec 23, 1996 Mar CAHN

&gt;D&gt; AB +! VALEANT PHARMS NORTH 10%

N019931 001 Dec 23, 1996 Mar CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

&gt;D&gt; @ TEVA PHARMS USA 80MG/ML;16MG/ML

A073303 001 Oct 31, 1991 Mar CMFD

&gt;A&gt; AP 80MG/ML;16MG/ML

A073303 001 Oct 31, 1991 Mar CMFD

SUMATRIPTAN SUCCINATE

TABLET;ORAL  
SUMATRIPTAN SUCCINATE

AB COREPHARMA EQ 25MG BASE

A200263 001 Jun 19, 2012 Feb CAHN

AB EQ 50MG BASE

A200263 002 Jun 19, 2012 Feb CAHN

AB EQ 100MG BASE

A200263 003 Jun 19, 2012 Feb CAHN

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL  
NUCYNTA

+ @ COLLEGIUM PHARM INC EQ 20MG BASE/ML

N203794 001 Oct 15, 2012 Feb CAHN

TABLET;ORAL  
NUCYNTA

+ COLLEGIUM PHARM INC EQ 50MG BASE

N022304 001 Nov 20, 2008 Feb CAHN

+ EQ 75MG BASE

N022304 002 Nov 20, 2008 Feb CAHN

+! EQ 100MG BASE

N022304 003 Nov 20, 2008 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL  
NUCYNTA ER

+ COLLEGIUM PHARM INC EQ 50MG BASE

N200533 001 Aug 25, 2011 Feb CAHN

+ EQ 100MG BASE

N200533 002 Aug 25, 2011 Feb CAHN

+ EQ 150MG BASE

N200533 003 Aug 25, 2011 Feb CAHN

+ EQ 200MG BASE

N200533 004 Aug 25, 2011 Feb CAHN

+! EQ 250MG BASE

N200533 005 Aug 25, 2011 Feb CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET; ORAL

TAZVERIK

+!	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	Jan	NEWA
----	-------------	---------------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

AP		SOMMER PHARMS II LLC	N/A	A206489	001	Feb 06, 2020	Jan	NEWA
----	--	----------------------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP		CURIUM	N/A	A078098	001	Sep 22, 2008	Feb	CAHN
----	--	--------	-----	---------	-----	--------------	-----	------

TELMISARTAN

TABLET; ORAL

TELMISARTAN

@ JUBILANT GENERICS

20MG

A204164	001	Aug 22, 2016	Jan	DISC
---------	-----	--------------	-----	------

@

40MG

A204164	002	Aug 22, 2016	Jan	DISC
---------	-----	--------------	-----	------

@

80MG

A204164	003	Aug 22, 2016	Jan	DISC
---------	-----	--------------	-----	------

TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

>D>								
>D>	+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Mar	DISC

>A>	+ @		EQ 50MG BASE	N211801	001	Sep 12, 2019	Mar	DISC
-----	-----	--	--------------	---------	-----	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

@ MYLAN

150MG

A206569	001	Nov 27, 2018	Feb	DISC
---------	-----	--------------	-----	------

@

200MG

A206569	002	Nov 27, 2018	Feb	DISC
---------	-----	--------------	-----	------

@

250MG

A206569	003	Nov 27, 2018	Feb	DISC
---------	-----	--------------	-----	------

@

300MG

A206569	004	Nov 27, 2018	Feb	DISC
---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ HERITAGE PHARMA

EQ 1MG BASE

A075614	002	Jan 30, 2001	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 2MG BASE

A075614	001	Jan 30, 2001	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 5MG BASE

A075614	003	Jan 30, 2001	Feb	DISC
---------	-----	--------------	-----	------

@

EQ 10MG BASE

A075614	004	Jan 30, 2001	Feb	DISC
---------	-----	--------------	-----	------

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

>D>	AB	MYLAN	7MG	A209702	001	Feb 28, 2020	Mar	DISC
-----	----	-------	-----	---------	-----	--------------	-----	------

>A>		@	7MG	A209702	001	Feb 28, 2020	Mar	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

	AB		7MG	A209702	001	Feb 28, 2020	Feb	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		14MG	A209702	002	Feb 28, 2020	Mar	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>		@	14MG	A209702	002	Feb 28, 2020	Mar	DISC
-----	--	---	------	---------	-----	--------------	-----	------

	AB		14MG	A209702	002	Feb 28, 2020	Feb	NEWA
--	----	--	------	---------	-----	--------------	-----	------

TERIPARATIDE

INJECTABLE; SUBCUTANEOUS

FORTEO

+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
----	-------	-------------------------	---------	-----	--------------	-----	------

@		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN
---	--	------------------------	---------	-----	--------------	-----	------

SOLUTION; SUBCUTANEOUS

BONSITY

ALVOGEN

0.62MG/2.48ML (0.25MG/ML)

N211939	001	Oct 04, 2019	Jan	CAIN
---------	-----	--------------	-----	------

FORTEO

+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CDFR
----	-------	-------------------------	---------	-----	--------------	-----	------

@		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CDFR
---	--	------------------------	---------	-----	--------------	-----	------

TESTOSTERONEGEL, METERED; TRANSDERMAL  
ANDROGEL

>D>	AB	+!	ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Mar	DISC
>A>		+ @		12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Mar	DISC
TESTOSTERONE									
>D>	AB		ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CTEC
>A>	BX	!		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CHRS
>A>	BX			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CTEC

TETRABENAZINETABLET; ORAL  
TETRABENAZINE

>A>	AB		APOTEX	12.5MG	A206093	001	Mar 17, 2020	Mar	NEWA
>A>	AB			25MG	A206093	002	Mar 17, 2020	Mar	NEWA
	AB		PIRAMAL HLTHCARE UK	12.5MG	A213316	001	Jan 22, 2020	Jan	NEWA
	AB			25MG	A213316	002	Jan 22, 2020	Jan	NEWA

TETRACYCLINE HYDROCHLORIDECAPSULE; ORAL  
TETRACYCLINE HYDROCHLORIDE

AB			STRIDES PHARMA	250MG	A212635	001	Mar 03, 2020	Feb	NEWA
AB				500MG	A212635	002	Mar 03, 2020	Feb	NEWA

THALLOUS CHLORIDE TL-201INJECTABLE; INTRAVENOUS  
THALLOUS CHLORIDE TL 201  
@ CURIUM

2mCi/ML

A077698 001 Nov 09, 2006 Feb CAHN

THIORIDAZINE HYDROCHLORIDETABLET; ORAL  
THIORIDAZINE HYDROCHLORIDE

>D>			MYLAN	10MG	A088004	002	Mar 15, 1983	Mar	CTEC
>A>	AB			10MG	A088004	002	Mar 15, 1983	Mar	CTEC
>D>				25MG	A088004	003	Mar 15, 1983	Mar	CTEC
>A>	AB			25MG	A088004	003	Mar 15, 1983	Mar	CTEC
>D>				50MG	A088004	004	Mar 15, 1983	Mar	CTEC
>A>	AB			50MG	A088004	004	Mar 15, 1983	Mar	CTEC
>D>		!		100MG	A088004	001	Nov 18, 1983	Mar	CTEC
>A>	AB	!		100MG	A088004	001	Nov 18, 1983	Mar	CTEC
>D>		@	SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Mar	CMFD
>A>	AB			10MG	A089953	004	Aug 01, 1986	Mar	CMFD
>D>		@		25MG	A089953	003	Aug 01, 1986	Mar	CMFD
>A>	AB			25MG	A089953	003	Aug 01, 1986	Mar	CMFD
>D>		@		50MG	A089953	002	Aug 01, 1986	Mar	CMFD
>A>	AB			50MG	A089953	002	Aug 01, 1986	Mar	CMFD
>D>		@		100MG	A089953	001	Oct 07, 1988	Mar	CMFD
>A>	AB			100MG	A089953	001	Oct 07, 1988	Mar	CMFD

THIOTEPAPOWDER; INTRAVENOUS  
TEPADINA

AP	+!		ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Feb	CFTG
AP	+!			100MG/VIAL	N208264	002	Jan 26, 2017	Feb	CFTG
THIOTEPA									
AP			MSN	15MG/VIAL	A213049	001	Mar 04, 2020	Feb	NFTG
AP				100MG/VIAL	A213049	002	Mar 04, 2020	Feb	NFTG

TICAGRELORTABLET; ORAL  
TICAGRELOR

>A>	AB		HEC PHARM CO LTD	90MG	A208508	001	Apr 06, 2020	Mar	NEWA
>A>	AB		SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Mar	NEWA

TIZANIDINE HYDROCHLORIDECAPSULE; ORAL  
TIZANIDINE HYDROCHLORIDE

>A>	AB		AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020	Mar	NEWA
>A>	AB			EQ 4MG BASE	A213544	002	Mar 24, 2020	Mar	NEWA
>A>	AB			EQ 6MG BASE	A213544	003	Mar 24, 2020	Mar	NEWA

TOBRAMYCINSOLUTION; INHALATION  
TOBRAMYCIN

@ MYLAN	300MG/5ML	A209554	001	Oct 13, 2017	Feb	DISC
---------	-----------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATEINJECTABLE; INJECTION  
TOBRAMYCIN SULFATE

AP	!	XGEN PHARMS	EQ 1.2GM BASE/VIAL	A065013	001	Aug 17, 2001	Feb	CAHN
----	---	-------------	--------------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

>D>		TOLAZAMIDE						
>D>		MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar	DISC
>A>		@	250MG	A070259	001	Jan 02, 1986	Mar	DISC
>D>	!		500MG	A070259	003	Mar 17, 1986	Mar	DISC
>A>		@	500MG	A070259	003	Mar 17, 1986	Mar	DISC

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

@ MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012	Jan	DISC	
@	2MG	A202641	002	Nov 27, 2012	Jan	DISC	
AB	UNIQUE PHARM LABS	1MG	A204721	001	Jan 24, 2020	Jan	NEWA
AB		2MG	A204721	002	Jan 24, 2020	Jan	NEWA

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

>D>	AB	APOTEX INC	25MG	A077733	001	Mar 27, 2009	Mar	CAHN
>D>	AB		50MG	A077733	002	Mar 27, 2009	Mar	CAHN
>D>	AB		100MG	A077733	003	Mar 27, 2009	Mar	CAHN
>D>	AB		200MG	A077733	004	Mar 27, 2009	Mar	CAHN
>A>	AB	VIWIT PHARM	25MG	A077733	001	Mar 27, 2009	Mar	CAHN
>A>	AB		25MG	A077733	001	Mar 27, 2009	Mar	CAHN
>A>	AB		50MG	A077733	002	Mar 27, 2009	Mar	CAHN
>A>	AB		50MG	A077733	002	Mar 27, 2009	Mar	CAHN
>A>	AB		100MG	A077733	003	Mar 27, 2009	Mar	CAHN
>A>	AB		100MG	A077733	003	Mar 27, 2009	Mar	CAHN
>A>	AB		200MG	A077733	004	Mar 27, 2009	Mar	CAHN
>A>	AB		200MG	A077733	004	Mar 27, 2009	Mar	CAHN

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB		COREPHARMA	5MG	A076894	001	May 31, 2005	Feb	CAHN
AB			10MG	A076894	002	May 31, 2005	Feb	CAHN
AB			20MG	A076894	003	May 31, 2005	Feb	CAHN
AB			100MG	A076894	004	May 31, 2005	Feb	CAHN

TRANEXAMIC ACIDINJECTABLE; INJECTION  
TRANEXAMIC ACID

@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan	DISC	
AP	XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb	CAHN

TABLET; ORAL

TRANEXAMIC ACID

@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan	CAHN
------------------	-------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB		AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan	NEWA
AB			100MG	A204852	002	Feb 05, 2020	Jan	NEWA
AB			150MG	A204852	003	Feb 05, 2020	Jan	NEWA
AB			300MG	A204852	004	Feb 05, 2020	Jan	NEWA

TRIAMCINOLONE ACETONIDE

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	ALLIED	0.1%	A040672	002	Dec 13, 2006	Mar CAHN
>A>	AT	SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETATE

>D>	AT	MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
>D>	AT		0.1%	A209828	002	Nov 23, 2018	Mar CTNA
>D>	AT		0.5%	A209828	003	Nov 23, 2018	Mar CTNA
>A>		TRIAMCINOLONE ACETONIDE					
>A>	AT	MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
>A>	AT		0.1%	A209828	002	Nov 23, 2018	Mar CTNA
>A>	AT		0.5%	A209828	003	Nov 23, 2018	Mar CTNA
>A>	AT	STRIDES PHARMA	0.1%	A211315	001	Mar 18, 2020	Mar NEWA
>A>	AT		0.5%	A211315	002	Mar 18, 2020	Mar NEWA

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

@ MYLAN PHARMS INC

0.125MG

A074031 001 Mar 25, 1994 Jan DISC

@

0.25MG

A074031 002 Mar 25, 1994 Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB		RISING	250MG	A212238	001	Feb 20, 2020	Feb NEWA
----	--	--------	-------	---------	-----	--------------	----------

URSODIOL

CAPSULE;ORAL

URSODIOL

AB		RISING	300MG	A213200	001	Feb 12, 2020	Jan NEWA
----	--	--------	-------	---------	-----	--------------	----------

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

@ TEVA PHARMS

EQ 500MG BASE

A077655 001 May 24, 2010 Jan DISC

@

EQ 1GM BASE

A077655 002 May 24, 2010 Jan DISC

>A>	AB	YILING PHARM LTD	EQ 500MG BASE	A209553	001	Mar 18, 2020	Mar NEWA
-----	----	------------------	---------------	---------	-----	--------------	----------

>A>	AB		EQ 1GM BASE	A209553	002	Mar 18, 2020	Mar NEWA
-----	----	--	-------------	---------	-----	--------------	----------

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		GRANULES PHARMS	50MG/ML	A213306	001	Jan 31, 2020	Jan NEWA
----	--	-----------------	---------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

PHARM ASSOC

EQ 500MG BASE/VIAL

A065401 001 Jun 30, 2008 Jan CAHN

EQ 1GM BASE/VIAL

A065401 002 Jun 30, 2008 Jan CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb NEWA
----	--	---------------------	------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Mar NEWA
-----	----	-------------------	----------------	---------	-----	--------------	----------

>A>	AB		EQ 75MG BASE	A203332	002	Mar 12, 2020	Mar NEWA
-----	----	--	--------------	---------	-----	--------------	----------

>A>	AB		EQ 150MG BASE	A203332	003	Mar 12, 2020	Mar NEWA
-----	----	--	---------------	---------	-----	--------------	----------

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

>A>	AP	AREVA PHARMS	10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Mar NEWA
-----	----	--------------	---------------------	---------	-----	--------------	----------

>A>	AP	CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020	Mar NEWA
-----	----	--------	--------------------	---------	-----	--------------	----------

>A>	AP		10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020	Mar NEWA
-----	----	--	---------------------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILAZODONE HYDROCHLORIDE

>D>	AB	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Mar	DISC
>A>		@	10MG	A208212	001	Sep 30, 2019	Mar	DISC
>D>	AB		20MG	A208212	002	Sep 30, 2019	Mar	DISC
>A>		@	20MG	A208212	002	Sep 30, 2019	Mar	DISC
>D>	AB		40MG	A208212	003	Sep 30, 2019	Mar	DISC
>A>		@	40MG	A208212	003	Sep 30, 2019	Mar	DISC

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

AP	!	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Feb	CTEC
AP		TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Feb	CMFD

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

>A>	AP	GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020	Mar	NEWA
-----	----	------------------	------------	---------	-----	--------------	-----	------

ZALEPLON

CAPSULE; ORAL

ZALEPLON

>D>	AB	TEVA PHARMS	5MG	A077239	001	Jun 06, 2008	Mar	DISC
>A>		@	5MG	A077239	001	Jun 06, 2008	Mar	DISC
>D>	AB		10MG	A077239	002	Jun 06, 2008	Mar	DISC
>A>		@	10MG	A077239	002	Jun 06, 2008	Mar	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

>D>		@ CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Mar	CMFD
>A>	AB		EQ 20MG BASE	A208988	001	Aug 22, 2017	Mar	CMFD
>D>		@	EQ 40MG BASE	A208988	002	Aug 22, 2017	Mar	CMFD
>A>	AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Mar	CMFD
>D>		@	EQ 60MG BASE	A208988	003	Aug 22, 2017	Mar	CMFD
>A>	AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Mar	CMFD
>D>		@	EQ 80MG BASE	A208988	004	Aug 22, 2017	Mar	CMFD
>A>	AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Mar	CMFD

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

AP		INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb	NEWA
----	--	--------------------	-----------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

>A>	AB	APPCO	2.5MG	A206973	001	Jun 30, 2017	Mar	CAHN
>A>	AB		5MG	A206973	002	Jun 30, 2017	Mar	CAHN
>D>	AB	TWI PHARMS	2.5MG	A206973	001	Jun 30, 2017	Mar	CAHN
>D>	AB		5MG	A206973	002	Jun 30, 2017	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

@ MYLAN	2.5MG
@	5MG

A202855	001	Sep 20, 2019	Feb	DISC
A202855	002	Sep 20, 2019	Feb	DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

>D>		@ AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Mar	CMFD
>A>	AB		25MG	A077645	002	Sep 29, 2006	Mar	CMFD
>D>		@	50MG	A077645	003	Sep 29, 2006	Mar	CMFD
>A>	AB		50MG	A077645	003	Sep 29, 2006	Mar	CMFD
>D>		@	100MG	A077645	001	Dec 22, 2005	Mar	CMFD
>A>	AB		100MG	A077645	001	Dec 22, 2005	Mar	CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+! PFIZER INC 250MG;125MG N211733 001 Feb 28, 2020 Feb NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

&gt;A&gt; GLENMARK GENERICS 0.1% A091314 001 Jul 01, 2010 Mar CMS1

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

&gt;D&gt; @ PERRIGO R AND D 5MG;120MG A210719 001 Nov 16, 2018 Mar CMFD

&gt;A&gt; 5MG;120MG A210719 001 Nov 16, 2018 Mar CMFD

DICLOFENAC SODIUM

GEL;TOPICAL

VOLTAREN

&gt;A&gt; +! GLAXOSMITHKLINE CONS 1% N022122 001 Oct 17, 2007 Mar CMS1

&gt;A&gt; VOLTAREN ARTHRITIS PAIN

&gt;A&gt; +! GLAXOSMITHKLINE CONS 1% N022122 001 Oct 17, 2007 Mar CTNA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

DR REDDYS LABS LTD 10MG

A077367 002 Aug 17, 2001 Jan CMS1

@ MYLAN 10MG

A075674 001 Dec 21, 2001 Jan DISC

&gt;D&gt; TEVA 10MG A075312 001 May 31, 2001 Mar DISC

&gt;A&gt; @ 10MG A075312 001 May 31, 2001 Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO 60MG

A212971 001 Feb 24, 2020 Feb NEWA

180MG

A212971 002 Feb 24, 2020 Feb NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

&gt;A&gt; AUROBINDO PHARMA LTD 600MG;60MG A213203 001 Mar 25, 2020 Mar NEWA

&gt;A&gt; 1.2GM;120MG A213203 002 Mar 25, 2020 Mar NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

PERRIGO R AND D 5MG

A211983 001 Mar 28, 2019 Feb CMFD

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

APOTEX 1.5MG

A205329 001 Sep 18, 2018 Jan CMFD

LABORATOIRE HRA 1.5MG

A204044 001 Jul 03, 2018 Jan CAHN

XIROMED 1.5MG

A205329 001 Sep 18, 2018 Feb CAHN

LORATADINE

TABLET;ORAL

LORATADINE

@ MYLAN 10MG

A075790 001 Nov 07, 2008 Jan DISC

@ 10MG

A078447 001 Aug 12, 2011 Jan DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

&gt;D&gt; YICHANG HUMANWELL 220MG A212033 001 Aug 30, 2019 Mar DISC

&gt;A&gt; @ 220MG A212033 001 Aug 30, 2019 Mar DISC



NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

DR REDDYS LABS SA

EQ 2MG BASE

A212983 001 Feb 21, 2020 Feb NEWA

EQ 4MG BASE

A212983 002 Feb 21, 2020 Feb NEWA

>D> NONOXYNOL-9

&gt;D&gt; SPONGE;VAGINAL

&gt;D&gt; TODAY

&gt;D&gt; +! MAYER LABS INC 1GM

N018683 001 Apr 01, 1983 Mar DISC

&gt;A&gt; + @ 1GM

N018683 001 Apr 01, 1983 Mar DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PATADAY

&gt;A&gt; +! NOVARTIS EQ 0.2% BASE

N021545 001 Dec 22, 2004 Mar CMS1

&gt;A&gt; PATADAY ONCE DAILY RELIEF

&gt;A&gt; +! NOVARTIS EQ 0.2% BASE

N021545 001 Dec 22, 2004 Mar CTNA

&gt;A&gt; PATADAY TWICE DAILY RELIEF

&gt;A&gt; +! NOVARTIS EQ 0.1% BASE

N020688 001 Dec 18, 1996 Mar CTNA

PATANOL

&gt;A&gt; +! NOVARTIS EQ 0.1% BASE

N020688 001 Dec 18, 1996 Mar CMS1

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

&gt;A&gt; HETERO LABS LTD III EQ 20MG BASE

A211732 001 Mar 25, 2020 Mar NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

&gt;D&gt; ACTAVIS ELIZABETH 20MG;1.1GM

A204137 001 Jul 15, 2016 Mar DISC

&gt;A&gt; @ 20MG;1.1GM

A204137 001 Jul 15, 2016 Mar DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

LANNETT CO INC

17GM/PACKET

A090600 001 Oct 06, 2009 Jan CMFD

17GM/SCOOPFUL

A090600 002 Oct 06, 2009 Jan CMFD

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2020**

NO MARCH 2020 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115	001				CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733	001				>A> NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	>A> 10588895	Jul 07, 2020	U-2772	>A> M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	>A> 10588895	Jan 14, 2022	U-2772		
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001	>A> 10561808	Jan 01, 2032	DP		
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	>A> 10561808	Jan 01, 2032	DP		
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002	>A> 10561808	Jan 01, 2032	DP		
		>A> 10569034	Aug 16, 2036	DP		
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001	>A> 10350214	Apr 24, 2035	DP		
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510	001	>A> 10525033	Mar 10, 2031	DP	NCE	Feb 26, 2025
		>A> 9084765	Mar 10, 2031	U-1744		
		>A> 9084765	Mar 10, 2031	U-2754		
		>A> 9545426	Mar 10, 2031	U-1744		
		>A> 9545426	Mar 10, 2031	U-2754		
		>A> 9889118	Mar 10, 2031	U-1744		
		>A> 9889118	Mar 10, 2031	U-2754		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001	10525057	Mar 08, 2034	U-1632		
		10525057	Mar 08, 2034	U-2723		
		10525057	Mar 08, 2034	U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	002	10525057	Mar 08, 2034	U-1632		
		10525057	Mar 08, 2034	U-2723		
		10525057	Mar 08, 2034	U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	003	10525057	Mar 08, 2034	U-1632		
		10525057	Mar 08, 2034	U-2723		
		10525057	Mar 08, 2034	U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	004	10525057	Mar 08, 2034	U-1632		
		10525057	Mar 08, 2034	U-2723		
		10525057	Mar 08, 2034	U-543		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10517507	Jun 13, 2032	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001 >A>	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002 >A>	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003 >A>	10583121	Jul 25, 2033	DP U-2763			
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001					PC	Aug 29, 2020
<u>BECLMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001 >A>	10561808	Jan 01, 2032	DP			
<u>BECLMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002 >A>	10561808	Jan 01, 2032	DP			
<u>BECLMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001 >A>	10561808	Jan 01, 2032	DP			
<u>BECLMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002 >A>	10561808	Jan 01, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEMPEDOIC ACID - NEXLETOI</u>						
N 211616 001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023	U-2747			
	9000041	Dec 23, 2023	U-2747			
	9624152	Dec 23, 2023	U-2748			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023	U-2746			
	9000041	Dec 23, 2023	U-2746			
	9624152	Dec 23, 2023	U-2749			
<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	>A> 10293047	Nov 15, 2037	DP U-2755			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	>A> 10617698	Jun 10, 2031	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	>A> 10398707	Apr 30, 2024	U-2759		>A> NP	Mar 04, 2023
	>A> 10441543	Dec 19, 2026	DP			
	>A> 7033605	Oct 20, 2020	DP			
	>A> 7799336	Apr 24, 2029	DP			
	>A> 8206737	Apr 07, 2027	U-2759			
	>A> 8629185	Jul 15, 2031	DS DP			
	>A> 8673341	Feb 19, 2025	U-2759			
	>A> 9149428	Dec 19, 2026	DP			
	>A> 9492316	Oct 31, 2034	DP			
	>A> 9980974	Oct 31, 2034	U-2759			
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569 001					NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10558394	Jun 25, 2031	DP			
	>A> 10592168	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	>A> 10592168	Jun 06, 2031	U-2489			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	>A> 10583110	Oct 27, 2030	U-2753			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001					>A> NPP	Nov 05, 2022
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001				>A> NPP		Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002				>A> NPP		Sep 13, 2022
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	>A> 7598279	Oct 30, 2027	DS			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	>A> 7598279	Oct 30, 2027	DS			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	>A> 7598279	Oct 30, 2027	DS			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	>A> 7598279	Oct 30, 2027	DS			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	>A> 7598279	Oct 30, 2027	DS			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	>A> 7598279	Oct 30, 2027	DS			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	>A> 10588914	Aug 31, 2030	DP U-2771			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	>A> 10590102	Jun 30, 2036	DS DP U-1776			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8039451*PED	Dec 11, 2026			>A> NPP	Mar 23, 2023
	8168614	Jan 20, 2030	U-1932		PED	Jun 14, 2022
	8168614*PED	Jul 20, 2030			>A> PED	Sep 23, 2023
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	>A> 10143665	Aug 16, 2036	U-1399		>A> M-216	Dec 22, 2020
	>A> 10328037	Aug 16, 2036	U-1399		>A> PED	Jun 22, 2021
	>A> 10548859	Aug 16, 2036	U-1399			
	>A> 8026284	Sep 22, 2027	U-1399			
	>A> 9173851	Jun 17, 2034	DP			
	>A> 9192590	Jan 26, 2027	U-1399			
	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9925156	Jan 26, 2027	DP U-1399			
	>A> 9925157	Jan 26, 2027	DP U-1399			
	>A> 9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	>A> 10143665	Aug 16, 2036	U-1399		>A> M-216	Dec 22, 2020
	>A> 10328037	Aug 16, 2036	U-1399		>A> PED	Jun 22, 2021
	>A> 10548859	Aug 16, 2036	U-1399			
	>A> 8026284	Sep 22, 2027	U-1399			
	>A> 9173851	Jun 17, 2034	DP			
	>A> 9192590	Jan 26, 2027	U-1399			
	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9925156	Jan 26, 2027	DP U-1399			
	>A> 9925157	Jan 26, 2027	DP U-1399			
	>A> 9925158	Jan 26, 2027	DP U-1399			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720			
	10478601	Apr 25, 2035	DP U-2721			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8673927	May 04, 2027			U-1652	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1652	
	9173859	May 04, 2027	DP		U-2730	
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP		U-2733	
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8673927	May 04, 2027			U-1652	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1652	
	9173859	May 04, 2027	DP		U-2730	
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP		U-2733	
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8673927	May 04, 2027			U-1652	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1652	
	9173859	May 04, 2027	DP		U-2730	
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP		U-2733	
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8673927	May 04, 2027			U-1652	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1652	
	9173859	May 04, 2027	DP		U-2730	
	9415016	Apr 02, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	9949998	Jun 11, 2034	U-2731			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP ODE-284 ODE-285	Sep 25, 2020 Sep 28, 2024 Sep 28, 2024
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001 >A>	10561651	Feb 19, 2035	U-2745			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002 >A>	10561651	Feb 19, 2035	U-2745			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	>A> 10568891	Jun 18, 2033	U-2316			
	>A> 10568891	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	>A> 10568891	Jun 18, 2033	U-2316			
	>A> 10568891	Jun 18, 2033	U-2317			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			
	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP U-2751			
	9050348	Jul 10, 2028	DP			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS U-2709			
	10519252	Oct 20, 2023	DS U-2710			
	10519252	Oct 20, 2023	DS U-2711			
	10519252	Oct 20, 2023	DS U-2712			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021	DP U-1577			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 10561808	Jan 01, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 10022510	May 18, 2031	DP			
	>A> 10124131	May 18, 2031	DP			
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10569034	Aug 16, 2036	DP			
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9731087	May 18, 2031	DP			
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 10022510	May 18, 2031	DP			
	>A> 10124131	May 18, 2031	DP			
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10569034	Aug 16, 2036	DP			
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9731087	May 18, 2031	DP			
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 10022510	May 18, 2031	DP			
	>A> 10124131	May 18, 2031	DP			
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10569034	Aug 16, 2036	DP			
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 9731087	May 18, 2031	DP			
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 6715485	Sep 03, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	>A> 10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	>A> 10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	>A> 10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	>A> 10561808	Jan 01, 2032	DP			
	>A> 10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	>A> 10561808	Jan 01, 2032	DP			
	>A> 10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	>A> 10561808	Jan 01, 2032	DP			
	>A> 10569034	Aug 16, 2036	DP			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	>A> 10568861	Jun 28, 2033	U-2756			
	>A> 10576054	Jun 28, 2033	U-2762			
	>A> 8518929	Feb 09, 2030	U-1287			
	>A> 8524698	Feb 09, 2030	U-1287			
	>A> 8546372	Feb 09, 2030	U-1287			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	>A> 10568861	Jun 28, 2033	U-2756			
	>A> 10576054	Jun 28, 2033	U-2762			
	>A> 8518929	Feb 09, 2030	U-1287			
	>A> 8524698	Feb 09, 2030	U-1287			
	>A> 8546372	Feb 09, 2030	U-1287			
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	>A> 7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	>A> 8748459	Mar 27, 2023	U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	>A> 7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	>A> 8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	>A> 10532993	Jul 11, 2026	U-1524			
	>A> 10588901	Mar 14, 2034	DS DP U-2773			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE; TETRACAIN - PLIAGLIS</u>						
N 021717 001	>A> 10603293	Jan 14, 2031	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	>A> 10596107	Dec 23, 2036	DP U-2764			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE39680	Jun 15, 2020	DS DP U-543			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	>A> 10596276	Jul 25, 2038	DP			
	>A> 10596278	Jul 25, 2038	DP			
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
	8512727	Dec 25, 2022	DP U-2750			
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	>A> 10561675	Aug 08, 2031	U-2490			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP U-2357			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10517882	Oct 01, 2030	U-2647			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209	001				>A> CGT	Sep 14, 2020
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051	001				I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254	001	>A> 10532993	Jul 11, 2026	U-1524		
		>A> 10588901	Mar 14, 2034	DS DP U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	6297375	Mar 17, 2023	DS		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001				>A> I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002				>A> I-825	Mar 09, 2023
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224	001	10342850	May 15, 2038	DP		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	001	8143241	Aug 12, 2027	U-2101	ODE-283	Dec 27, 2026
		8143241	Aug 12, 2027	U-2103		
		8143241	Aug 12, 2027	U-2480		
		8143241	Aug 12, 2027	U-2481		
		8143241	Aug 12, 2027	U-2482		
		8143241	Aug 12, 2027	U-2483		
		8143241	Aug 12, 2027	U-2716		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2480		
		8859562	Aug 04, 2031	U-2481		
		8859562	Aug 04, 2031	U-2482		
		8859562	Aug 04, 2031	U-2483		
		8859562	Aug 04, 2031	U-2716		
		9566276	Mar 12, 2024	U-2716		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	002	8143241	Aug 12, 2027	U-2101	ODE-283	Dec 27, 2026
		8143241	Aug 12, 2027	U-2103		
		8143241	Aug 12, 2027	U-2480		
		8143241	Aug 12, 2027	U-2481		
		8143241	Aug 12, 2027	U-2482		
		8143241	Aug 12, 2027	U-2483		
		8143241	Aug 12, 2027	U-2716		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2480		
		8859562	Aug 04, 2031	U-2481		
		8859562	Aug 04, 2031	U-2482		
		8859562	Aug 04, 2031	U-2483		
		8859562	Aug 04, 2031	U-2716		
		9566276	Mar 12, 2024	U-2716		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	001				M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	002				M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	003				M-251	Aug 02, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u> N 021246 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u> N 021246 002					M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u> N 212801 001					>A> NCE	Mar 06, 2025
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u> N 212801 002					>A> NCE	Mar 06, 2025
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u> N 212801 003					>A> NCE	Mar 06, 2025
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u> N 021611 001					>A> M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u> N 021611 002					>A> M-14	Oct 25, 2022
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u> N 209899 001					>A> NCE	Mar 25, 2025
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u> N 209899 002					>A> NCE	Mar 25, 2025
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u> N 209899 003					>A> NCE	Mar 25, 2025
<u>OZENOXACIN - XEPI</u> N 208945 001	>A> 6335447	Apr 06, 2021	DS			
<u>PALBOCICLIB - IBRANCE</u> N 207103 001	>A> 6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u> N 207103 002	>A> 6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u> N 207103 003	>A> 6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u> N 212436 001	>A> 6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u> N 212436 002	>A> 6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u> N 212436 003	>A> 6936612	Jan 16, 2023	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u> N 022264 001	>A> 9439906 >A> 9439906 >A> 9439906 >A> 9439906	Jan 26, 2031 Jan 26, 2031 Jan 26, 2031 Jan 26, 2031	U-1901 U-2757 U-2758 U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u> N 022264 002	>A> 9439906 >A> 9439906 >A> 9439906 >A> 9439906	Jan 26, 2031 Jan 26, 2031 Jan 26, 2031 Jan 26, 2031	U-1901 U-2757 U-2758 U-543			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	>A> 9439906	Jan 26, 2031	U-1901			
	>A> 9439906	Jan 26, 2031	U-2757			
	>A> 9439906	Jan 26, 2031	U-2758			
	>A> 9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	>A> 9439906	Jan 26, 2031	U-1901			
	>A> 9439906	Jan 26, 2031	U-2757			
	>A> 9439906	Jan 26, 2031	U-2758			
	>A> 9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	>A> 9439906	Jan 26, 2031	U-1901			
	>A> 9439906	Jan 26, 2031	U-2757			
	>A> 9439906	Jan 26, 2031	U-2758			
	>A> 9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	>A> 9439906	Jan 26, 2031	U-1901			
	>A> 9439906	Jan 26, 2031	U-2757			
	>A> 9439906	Jan 26, 2031	U-2758			
	>A> 9439906	Jan 26, 2031	U-543			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	>A> 10583207	Dec 28, 2035	U-665			
	>A> 10583208	Mar 16, 2037	U-665			
	>A> 10588988	May 04, 2037	U-665			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	>A> 8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	>A> 8759372	Feb 25, 2033	DS DP			
<u>RIVAROXBAN - XARELTO</u>						
N 022406 004					I-824	Oct 11, 2021
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10544108	Jul 26, 2032	U-2584			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001					I-822	Jan 16, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	002				I-822	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	001				M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	002				M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	003				M-252	Jan 16, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001				>A> NPP	Mar 19, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	002				>A> NS	Mar 19, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230	001	10512609	Sep 05, 2037		U-2548	
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230	002	10512609	Sep 05, 2037		U-2548	
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306	001	>A> 10512620	Aug 18, 2038		U-2769	
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884	001	>A> 10603305	Jun 16, 2030	DP	U-1719	
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223	001	10537554	Jan 29, 2036		U-72	
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001				M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002				M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003				M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004				M-253	Jan 29, 2023
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	001	>A> 8664239	Aug 30, 2028		U-1752	
		>A> 8664239	Aug 30, 2028		U-2677	
		>A> 8664239	Aug 30, 2028		U-2678	
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	002	>A> 8664239	Aug 30, 2028		U-1752	
		>A> 8664239	Aug 30, 2028		U-2677	
		>A> 8664239	Aug 30, 2028		U-2678	
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	003	>A> 8664239	Aug 30, 2028		U-1752	
		>A> 8664239	Aug 30, 2028		U-2677	
		>A> 8664239	Aug 30, 2028		U-2678	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZAROTENE - FABIOR</u>						
N 202428 001 >A>	10568859	Feb 24, 2030	DP U-2760			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Apr 13, 2032	U-2736		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2737			
	10369155	Oct 16, 2035	U-2736			
	10420775	Apr 13, 2032	U-2736			
	8410088	Apr 13, 2032	DS DP			
	9090562	Apr 13, 2032	DS DP			
	9394283	Apr 11, 2033	DS DP			
	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Apr 20, 2026	DS DP U-2507			
	7816379	Apr 20, 2026	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Apr 20, 2026	DS DP U-2507			
	7816379	Apr 20, 2026	DS DP U-282			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001					M-255	Feb 04, 2023
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001 >A>	10588975	Mar 13, 2026	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP	U-2717		
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP	U-2718		
	9833448	Nov 10, 2031		U-2718		
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP	U-2717		
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP	U-2718		
	9833448	Nov 10, 2031		U-2718		
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP	U-839	M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022		U-839		
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022		U-839		
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP	U-839	M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022		U-839		
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022		U-839		
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP	U-839	M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022		U-839		
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022		U-839		
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10493035	Oct 12, 2037	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034		U-2676		
	9248199	Jan 29, 2034		U-2715		
	9447071	Feb 06, 2035	DS DP			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)